



Published in final edited form as:

*Nature*. 2023 September ; 621(7977): 179–187. doi:10.1038/s41586-023-06483-w.

## Metabolic Programs of T Cell Tissue Residency Empower Tumor Immunity

Miguel Reina-Campos<sup>1</sup>, Maximilian Heeg<sup>1</sup>, Kelly Kennewick<sup>2</sup>, Ian T. Mathews<sup>3,4,5</sup>, Giovanni Galletti<sup>1</sup>, Vida Luna<sup>1</sup>, Quynhanh Nguyen<sup>1</sup>, Hongling Huang<sup>6</sup>, J. Justin Milner<sup>7</sup>, Kenneth H. Hu<sup>8</sup>, Amy Vichaidit<sup>2</sup>, Natalie Santillano<sup>2</sup>, Brigid S. Boland<sup>4</sup>, John T. Chang<sup>4</sup>, Mohit Jain<sup>4,5</sup>, Sonia Sharma<sup>3</sup>, Matthew F. Krummel<sup>8</sup>, Hongbo Chi<sup>6</sup>, Steven J. Bensinger<sup>2</sup>, Ananda W. Goldrath<sup>1</sup>

<sup>1</sup>School of Biological Sciences, Department of Molecular Biology, University of California San Diego; San Diego, CA, USA.

<sup>2</sup>Department of Medicine, David Geffen School of Medicine at UCLA; Los Angeles, California, USA.

<sup>3</sup>La Jolla Institute for Immunology; La Jolla, CA, USA.

<sup>4</sup>Department of Medicine, University of California San Diego; La Jolla, CA, USA.

<sup>5</sup>Department of Pharmacology, University of California San Diego; La Jolla, CA, USA.

<sup>6</sup>Department of Immunology, St. Jude Children's Research Hospital; Memphis, TN, USA.

<sup>7</sup>Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill School of Medicine; Chapel Hill, NC, USA.

<sup>8</sup>Department of Pathology, University of California San Francisco; San Francisco, CA, USA.

### Abstract

Tissue-resident memory CD8 T cells ( $T_{RM}$ ) offer rapid and long-term protection at sites of re-infection<sup>1</sup>. Tumor-infiltrating lymphocytes (TIL) with characteristics of  $T_{RM}$  maintain enhanced effector functions, predict responses to immunotherapy, and accompany better prognoses<sup>2,3</sup>. Thus, an improved understanding of the metabolic strategies that enable tissue residency by T cells

---

Corresponding author's, Ananda W. Goldrath: [agoldrath@ucsd.edu](mailto:agoldrath@ucsd.edu).

Author contributions

Conceptualization: MR-C, AG

Methodology: MR-C, KTK, IM, KH, GG, AG, SS, MJ, MK, HC

Investigation: MR-C, KTK, IM, VL, QN, GG, HH, JM, KH, AV, NS, BB

Visualization: MR-C, MH, KTK, IM, GG

Funding acquisition: MR-C, AG, JC, SS, MK, HC, SJB

Project administration: AG

Supervision: MR-C, AG

Writing – original draft: MR-C and AG

Writing – review & editing: MR-C, MH, GG, HC, SS, SJB, AG

Competing interests

A.W.G. serves on the scientific advisory boards of ArsenalBio and Foundery Innovations. H.C. is a consultant for Kumquat Biosciences. M.F.K. is a founder and shareholder of PIONYR Immunotherapeutic and Foundery Innovations. A provisional patent application has been filed by M.R-C., G.G, and A.G. covering the methods of use of *FDFT1* and *PDSS2* manipulation for “ENHANCING CAR-T CELL PERFORMANCE FOR CANCER IMMUNOTHERAPY” (U.S. Provisional Application Serial No. 63/449,701). The rest of the authors declare that they have no competing interests.

could inform new approaches to empower immune responses in tissues and solid tumors. To systematically define the basis for the metabolic reprogramming supporting  $T_{RM}$  differentiation, survival, and function, we leveraged *in vivo* functional genomics, untargeted metabolomics, and transcriptomics of virus-specific memory CD8 T cell populations. We found that memory CD8 T cells deployed a range of adaptations to tissue residency, including reliance on non-steroidal products of the mevalonate/cholesterol pathway, such as Coenzyme Q (CoQ), driven by increased activity of the transcription factor Srebp2. This metabolic adaptation was most pronounced in the small intestine (SI), where  $T_{RM}$  interface with dietary cholesterol and maintain a heightened state of activation<sup>4</sup>, and was shared by functional TIL in diverse tumor types in mice and humans. Enforcing CoQ synthesis through *Fdft1* deletion or *Pdss2* overexpression promoted mitochondrial respiration, memory formation upon viral infection, and enhanced antitumor immunity. In sum, through a systematic exploration of  $T_{RM}$  metabolism, we reveal how these programs can be leveraged to fuel CD8 T cell memory formation in the context of acute infections and enhance antitumor immunity.

To maximize immune protection, memory CD8 T cells differentiate into functionally distinct populations with different surveillance capacities. These include effector memory T cells ( $T_{EM}$ ) that mostly recirculate through tissues, central memory T cells ( $T_{CM}$ ) that act as sentinels in lymphoid organs, and  $T_{RM}$ , which become a permanent asset to tissues throughout the body<sup>1</sup>.  $T_{RM}$  constitute the majority of the CD8 T cell memory pool<sup>5</sup>, can retain the potential for supernumerary division and longevity<sup>6,7</sup>, and offer a rapid and potent first line of defense due to their proximity to sites of reinfection and enhanced cytotoxic potential<sup>8–13</sup>, mediating protection against viral and bacterial infections<sup>8–11,14–17</sup>. Similarly in tumors, pre-existing  $T_{RM}$  as well as TIL with  $T_{RM}$  features ( $T_{RM}$ -like) play a crucial role in suppressing the emergence of malignancies and mediating tumor control upon immune checkpoint blockade due to their superior intrinsic functional activity<sup>3,17–21</sup>. The different environments in which these memory CD8 T cell subsets reside condition their function and differentiation<sup>22</sup>, potentially imposing distinct metabolic adaptations that support cell fitness. In addition, cellular metabolism can steer the course of CD8 T cell differentiation by linking specific enzymes and metabolites to cell fates and functions<sup>22,23</sup>. Thus, an understanding of such mechanisms offers actionable strategies to program T cell subtypes that augment protection against infection and enhance current immunotherapies. While the major transcriptional programs that guide  $T_{RM}$  differentiation are established<sup>4,17,24–27</sup>, a systematic investigation of the metabolic changes that allow  $T_{RM}$  formation and function is lacking.

## A systematic profiling of $T_{RM}$ metabolism

The transcriptional and functional inter-tissue heterogeneity of  $T_{RM}$ <sup>24,27</sup> indicate that metabolic adaptations to diverse tissue environments accompany their differentiation. Indeed, we observe activation-dependent and tissue-specific gene-expression changes of metabolic signatures by different lymphocytic choriomeningitis virus (LCMV)-specific CD8 T cell subsets (Extended Data Fig. 1a). To uncover the functional metabolic regulators of  $T_{RM}$  formation, we performed a pooled CRISPR/Cas9-mediated loss-of-function screen targeting 3017 metabolic genes in the context of LCMV infection *in vivo* (Fig. 1a). We utilized P14

T cell receptor transgenic CD8 T cells, specific for the LCMV glycoprotein 33–41 peptide (GP<sub>33–41</sub>) presented by H2-D<sup>b</sup>, that constitutively expressed Cas9, allowing gene-editing by CRISPR/Cas9 (P14 Cas9eGFP). P14 Cas9eGFP cells transduced with the metabolic regulator targeting sgRNA library were adoptively transferred into WT recipients that were then infected with LCMV-Armstrong. Two weeks after infection, sgRNA-transduced P14 Cas9eGFP T cells were recovered, including circulating memory populations T<sub>EM</sub>, T<sub>CM</sub>, and t-T<sub>EM</sub> from the spleen; small intestine (SI) T<sub>RM</sub>, and liver T<sub>RM</sub> and T<sub>EM</sub>, allowing comparison of circulating to tissue-resident populations as well as comparison of two different tissue-resident populations. At this time point, P14 Cas9eGFP cells have seeded peripheral tissues and show a T<sub>RM</sub> phenotype while allowing sufficient cell recovery<sup>17</sup> (Fig. 1a). Intravenous (IV) labeling of CD8 T cells before cell isolation allowed discrimination of tissue-localized T<sub>RM</sub> (IV<sup>-</sup>) from cells in circulation<sup>5</sup>. Consistent with a process of *in vivo* selection, sgRNA frequencies were more heterogeneous in the recovered memory populations than in the input populations (Extended Data Fig. 1b). To assess the impact of each gene on memory T cell subsets, individual sgRNA abundance for each sample was compared to the initial input to calculate Log<sub>2</sub> Fold Change (Log<sub>2</sub>FC) enrichment and pooled to obtain gene-level scores. We focused first on the 155 metabolic genes that were statistically significant in their impact on SI T<sub>RM</sub> formation (Fig. 1b and Supplementary Table 1). Most gene disruptions showed detrimental effects on memory CD8 T cell formation irrespective of subset or tissue (Fig. 1b). Unsupervised clustering grouped SI and liver T<sub>RM</sub> together, suggesting that, despite clear differences between these two tissues, T<sub>RM</sub> were metabolically different from circulatory populations (Fig. 1b). Further, a subset of genes was uniquely depleted in SI T<sub>RM</sub>, including Cardiolipin synthase 1 (*Crls1*), a metabolic regulator known to support the mitochondrial function of SI T<sub>RM</sub><sup>4</sup> (Fig. 1b). Finally, 6 genes led to increased SI T<sub>RM</sub> formation when disrupted (Fig. 1b and Extended Data Fig. 1c). These genes included known negative regulators of CD8 T cell function and proliferation, such as Regnase-1 (*Zc3h12a*)<sup>28</sup>, *Pter*<sup>29</sup>, and *Inpp5d*<sup>30</sup>. To gain a higher-level view of the processes represented by these individual gene scores, we classified each target by metabolic pathway (Supplementary Table 2). Among the positive metabolic regulators of SI T<sub>RM</sub>, the “Oxidative phosphorylation complex III (OXPHOS Complex III)” and the “mevalonate/cholesterol synthesis” pathways were highly enriched in SI T<sub>RM</sub> (Fig. 1c and Supplementary Table 3).

Next, we determined the relative abundance of intracellular metabolites in *ex vivo* populations of T<sub>RM</sub> from the SI and kidney, and T<sub>EM</sub>, T<sub>CM</sub> and t-T<sub>EM</sub> from the spleen by untargeted metabolomics (Extended Data Fig. 1d). Principal component analysis (PCA) of metabolite composition of these populations revealed a separation among T<sub>RM</sub> and circulatory memory CD8 T cell fractions along PC1, and separation between kidney and SI T<sub>RM</sub> along PC2 (Fig. 1d). In agreement with our transcriptional and functional data, these data suggested that T<sub>RM</sub> in general have a distinct metabolic profile compared to their circulatory counterparts, as well as unique profiles associated with specific tissues. Unsupervised clustering based on identified, annotated metabolites revealed a similar sample aggregation and highlighted key intermediaries of the mevalonate/cholesterol synthesis pathway, mevalonate and mevalonolactone (loss-of-water adduct of mevalonate), as elevated in T<sub>RM</sub>, and SI T<sub>RM</sub>, respectively (Fig. 1e, Extended Data Fig. 1e, f, and Supplementary

Table 4). Thus, data from our functional screen as well as gene expression and metabolomics profiling each revealed increased mevalonate/cholesterol synthesis as a potential metabolic adaptation of SI T<sub>RM</sub>.

Rapid generation of mevalonate-derived products, including cholesterol, is required for initial rapid CD8 T cell proliferation after TCR activation<sup>31</sup>. Consistent with this, the transcriptional upregulation of enzymes of this pathway peaked early after LCMV infection, followed by a decline as CD8 T cells differentiate into memory CD8 T cell populations, with the notable exception of SI T<sub>RM</sub>, where expression remained elevated well after resolution of infection (Fig. 1f and Extended Data Fig. 2a, b). Sustained expression of the mevalonate/cholesterol synthesis pathway was not unique to SI T<sub>RM</sub>, as T<sub>RM</sub> from other tissues maintained enrichment of this pathway compared to circulating memory CD8 T cell populations in the spleen and blood, however to a lesser degree (Fig. 1g and Extended Data Fig. 2c,d). Multiple data sets of mouse and human CD8 T cells showed similar enrichment patterns for expression of genes in the mevalonate/cholesterol synthesis pathway (Extended Data Fig. 2a–f).

Expression of the enzymes of the mevalonate/cholesterol synthesis pathway are collectively enhanced by the transcription factor (TF) sterol regulatory element binding protein 2 (Srebp2, encoded by *Srebf2*). Bioinformatics analysis by Taiji<sup>32</sup>, which leverages chromatin accessibility data combined with RNA expression, predicted Srebp2 as an upstream regulator of gene expression in SI T<sub>RM</sub><sup>24</sup> (Fig. 1h). Srebp2 protein was more abundant in T<sub>RM</sub> of the SI compared to those of the kidney, and CD8 T cells in the spleen (Fig. 1i). Similarly, protein levels of Hmgcr, an Srebp2 target, and the rate-limiting enzyme of the mevalonate/cholesterol synthesis pathway, were also higher in human SI and colonic CD8 T cells compared to those in the spleen (Extended Data Fig. 2g). Runx3, necessary for the programming of CD8 T cell tissue residency<sup>17</sup>, also regulated expression of mevalonate/cholesterol pathway enzymes by CD8 T cells (Extended Data Fig. 2h). Thus, T<sub>RM</sub> possessed a distinct metabolic program compared to their circulatory counterparts, including adaptations more prevalent in certain tissues, such as enrichment of the mevalonate/cholesterol synthesis pathway driven by Srebp2, which was most active in SI T<sub>RM</sub>.

### Srebp2 promotes T<sub>RM</sub> formation

To functionally assess the contribution of Srebp2 to T<sub>RM</sub> formation, we adoptively transferred a 1:1 mix of P14 T cells transduced with control *Cd19* shRNAmir- or *Srebf2* shRNAmir-encoding retroviruses into mice that were subsequently infected with LCMV (Fig. 2a). *Srebf2* shRNAmir suppressed *Srebf2* expression as well as its downstream target *Hmgcr* by 5–10-fold (Extended Data Fig. 3a), and impaired T<sub>RM</sub> formation in the SI with minimal impact on T cell accumulation in kidney, WAT, or liver (Fig. 2a). CD8 T cell populations in the spleen were unaffected by *Srebf2* KD at both effector and memory time points (Extended Data Fig. 3b,c). However, full deletion of *Srebp2* (P14 CD8 T cells transduced with control (*sgCd19*) or *Srebf2* sgRNA-encoding retroviruses (*sgSrebf2*)), impaired T<sub>RM</sub> formation in SI, kidney and WAT, but spared circulatory memory CD8 T cell populations despite decreased effector T cell accumulation at day 7 (Fig. 2b and Extended

Data Fig. 3d–f). Liver T<sub>RM</sub> showed less dependence on Srebp2; IV<sup>-</sup> P14 CD8 T cells were modestly impaired and when defined as CD69<sup>+</sup>CD62L<sup>-</sup>, an alternative gating strategy<sup>33</sup>, liver T<sub>RM</sub> were unaffected by loss of Srebp2 (Fig. 2b). SI T<sub>RM</sub> populations induced by *Listeria monocytogenes* (LM) infection also required Srebp2, suggesting the reliance on this pathway in infection was generalizable (Fig. 2c). Together, these results showed that sustained Srebp2 expression was functionally relevant for the formation of T<sub>RM</sub> but not for circulating memory T cell populations.

The inactive form of Srebp2 in the endoplasmic reticulum (ER) becomes activated under conditions of low ER cholesterol by its translocation to the Golgi by Srebp activating-cleavage protein (Scap)<sup>34</sup>, and thus loss of Scap impairs Srebp2 activation<sup>34</sup>. To understand the implications of mevalonate/cholesterol synthesis inhibition in polyclonal endogenous CD8 T cell responses, we infected mice with a T cell-specific deletion of Scap (*Scap*<sup>fl/fl</sup> *Cd4-Cre*<sup>+</sup>, Scap KO) and followed the LCMV-specific CD8 T cell response of H-2D<sup>b</sup>-GP<sup>33-41</sup> tetramer (Tet<sup>+</sup>) compared to WT (*Scap*<sup>wt</sup> *Cd4-Cre*<sup>+</sup>) mice. As previously shown<sup>33</sup>, Tet<sup>+</sup> Scap KO cells displayed reduced accumulation during the effector phase compared to WT Tet<sup>+</sup> cells<sup>31</sup> (Fig. 2d and Extended Data Fig. 3g). Scap KO showed impaired differentiation of Tet<sup>+</sup> CD103<sup>+</sup>CD69<sup>+</sup> SI T<sub>RM</sub>, but not kidney or liver T<sub>RM</sub> (Fig. 2d, Extended Data Fig. 3h). Concomitant with impaired T<sub>RM</sub> accumulation, Scap KO mice that had been infected with LM-GP<sup>33-41</sup> had higher viral titers in the SI when rechallenged with LCMV compared to WT mice (Fig. 2e). While loss of Scap reduces fatty acid synthesis, as it also controls Srebp1 (*Srebf1*) activity, neither *Srebf1* nor Fatty Acid Synthase (*Fasn*) impacted memory T cell differentiation (Supplementary Table 1).

Hmgcr inhibitors (statins) are widely consumed lipid-lowering drugs with known immunomodulatory effects<sup>35</sup>. We found that lovastatin treatment impaired the accumulation of P14 CD8 T cells responding to LCMV in the SI compared to the control group on day 7 of infection; by day 21 there was a sustained loss of SI T<sub>RM</sub> and impaired accumulation of memory T cells in the spleen as well (Fig. 2f). These observations are of potential human significance as we observed lower expression of the T<sub>RM</sub> gene-expression signature<sup>17</sup> in SI CD8 T cells from statin users than non-statin users, revealing a potentially underappreciated effect of statins on T<sub>RM</sub> populations of the SI (Fig. 2g and Supplementary Table 5).

Each of these conditions inhibit the mevalonate/cholesterol synthesis pathway to varying degrees. Combined, these data suggested that enhanced activity downstream of Hmgcr, Scap, and Srebp2 is a metabolic requirement of CD8 T cells to become SI T<sub>RM</sub>. We observed graded reliance on Srebp2 among the different tissues; where SI T<sub>RM</sub> showed a greater dependence on the pathway than kidney, WAT, and liver resident cells, reflecting the pattern of expression for genes involved in this pathway (Fig. 1g).

Interestingly, enforcing Srebp2 activity by ectopic overexpression of a constitutively active nuclear isoform actually prevented P14 CD8 T cell accumulation in the SI after LCMV infection, despite successfully increasing total cellular cholesterol and its downstream target, LDLR (Extended Data Fig. 3i, j). This additional observation is consistent with the idea that generating high cholesterol levels may not be the rate-limiting step for T<sub>RM</sub> populations. To further investigate the impact of Srebp2 loss, we compared gene expression by sh*Cd19*

or sh*Srebf2*-transduced P14 CD8 T cells after LCMV infection. *Srebf2* and the mevalonate/cholesterol synthesis pathway-associated enzymes were most highly expressed in SI T<sub>RM</sub> and reduced in the sh*Srebf2*-transduced P14 CD8 T cells (Extended Data Fig. 4a–c), and a core T<sub>RM</sub> gene-expression signature<sup>17</sup> was downregulated in sh*Srebf2* P14 CD8 T cells in the SI (Extended Data Fig. 4d–e). Strikingly, few genes were differentially expressed beyond *Srebp2* and *Srebp2*-dependent genes (Extended Data Fig. 4f), suggesting that impaired SI T<sub>RM</sub> accumulation upon *Srebp2* knockdown was not likely the result of transcriptional changes beyond the mevalonate/cholesterol synthesis pathway.

SI T<sub>RM</sub> are unique in their close contact with food-derived nutrients in the absorptive lining of the intestine<sup>36</sup>. Given that *Srebp2* activity is regulated by the strong inhibitory feedback exerted by cholesterol (present in the diet), we sought to understand how the intestinal environment affected *Srebp2*-dependent metabolic programs on SI T<sub>RM</sub>. Notably, memory P14 CD8 T cells in the SI, but not the spleen, showed significant uptake of orally administered cholesterol (Extended Data Fig. 5a). On the other hand, when administered IV, none of the memory CD8 T cell populations profiled, including SI T<sub>RM</sub>, showed significant *in vivo* uptake of cholesterol-containing low-density lipoproteins (LDL), the main form of systemic delivery of cholesterol to cells (Extended Data Fig. 5b). Using imaging flow cytometry, we found that SI T<sub>RM</sub> of mice fed regular chow had the lowest amount of intracellular cholesterol compared to the kidney, liver, and splenic population (Extended Data Fig. 5c), consistent with maintained *Srebp2* activity. Feeding a high cholesterol-containing diet partially reduced *Srebp2*-dependent genes, *Hmgcr*, *Hmgcs1*, and *Ldlr* in CD8 T cells of the SI, with minimal effects in splenic CD8 T cells (Extended Data Fig. 5d) and impaired SI T<sub>RM</sub>, but not kidney or liver T<sub>RM</sub>, formation and maintenance (Fig. 2h and Extended Data Fig. 5e,f). Of note, the diet high in cholesterol did not impact food intake or mouse weight, and only transiently raised circulating cholesterol levels compared to the low cholesterol diet control (Extended Data Fig. 5g–i). Ultra-low input (ULI)-RNAseq analysis of SI T<sub>RM</sub> from mice fed a high cholesterol diet showed marked suppression of *Srebp2* targets, as well as induction of programmed cell death-related genes and cholesterol efflux transporters, compared SI T<sub>RM</sub> from mice fed a low cholesterol diet (Extended Data Fig. 5j–l and Supplementary Table 6). Thus, SI T<sub>RM</sub> take up and adapt to differences in dietary cholesterol, but when in excess, either by enforcing *Srebp2* OE (Extended Data Fig. 3i) or over-feeding (Fig. 2h), cholesterol was detrimental to SI T<sub>RM</sub> accumulation. While increasing cholesterol in the diet attenuated *Srebp2* activity, it was insufficient to reduce it to levels observed in the spleen (Extended Data Fig. 5d) suggesting additional cues, beyond environmental cholesterol, likely maintain *Srebp2* activity in this environment, such as *Runx3* (Extended Data Fig. 2g). Further, these data suggested that, rather than cholesterol, alternative products of the mevalonate/cholesterol synthesis pathway are the relevant mediators of T<sub>RM</sub> formation downstream of *Srebp2*.

### SI T<sub>RM</sub> rely on CoQ-producing enzymes

Intermediate products of the mevalonate/cholesterol synthesis pathway supply substrates to produce important nonsterol isoprenoids, such as CoQ, through branched reactions. To explore the mechanistic basis for T<sub>RM</sub> dependence encompassing these alternative fates of mevalonate, we focused on additional enzymes that regulate diversion of intermediates to

synthesis of non-steroidal metabolites from the *in vivo* CRISPR/Cas9 (extended mevalonate/cholesterol synthesis pathway) (Fig. 3a and Extended Data Fig. 6a). Clustering of these genes by their relative impact on CD8 T cell memory populations revealed a group that were more specific to SI T<sub>RM</sub> (Fig. 3a). Among these genes, *Pdss2* and *Hpd*, two enzymes that divert metabolites to the synthesis of CoQ, were both particularly required for SI T<sub>RM</sub>, and targeting led to similar loss of T<sub>RM</sub> phenotypes as disruption of *Srebf2* and *Scap* (Fig. 3a). Notably, our metabolomics analysis found 4-hydroxybenzaldehyde (4-Hb), the product of *Hpd* enzyme, to be especially elevated in SI T<sub>RM</sub> compared to other CD8 T cell populations, indicating this pathway might be increased in SI T<sub>RM</sub> (Extended Data Fig. 6b,c). Validation of the CRISPR/Cas9 screen by targeting *Hpd* revealed impaired formation of SI T<sub>RM</sub>, but not P14 memory T cells in the spleen, liver, or kidney (Fig. 3b and Extended Data Fig. 6d). These results suggested SI T<sub>RM</sub> have a heightened requirement for CoQ synthesis compared to other memory CD8 T cell populations. Further, deletion of squalene synthase (*Fdft1*), which catalyzes the first step of the isoprenoid branch committed specifically to cholesterol production, appeared to promote several populations of memory CD8 T cells (Fig. 3a). Consistent with the CRISPR/Cas9 screen, targeting *Fdft1* resulted in increased accumulation of liver T<sub>RM</sub>, as well as circulating memory subsets, but it was not sufficient to further enhance SI T<sub>RM</sub> (Fig. 3c and Extended Data Fig. 6e). These data reinforce the notion that the production of cholesterol by the mevalonate pathway is not required and revealed a metabolic enzyme, *Fdft1*, to be a potentially actionable target to improve memory CD8 T cell formation.

To gain greater insight into the identity and mechanism of action of the relevant non-steroidal products mediating greater memory potential to *Fdft1* KO CD8 T cells, we conducted a secondary targeted *in vivo* CRISPR/Cas9 screen of potential non-steroidal mediators of *Fdft1* impact on T cell accumulation. This library, composed of 153 sgRNAs targeting 50 genes of the extended mevalonate/cholesterol synthesis pathway (Extended Data Fig. 6a and Supplementary Table 7), was transduced into either control (sg*Cd19*) or sg*Fdft1* P14 Cas9eGFP T cells to test their function in mediating *Fdft1*-enhanced T<sub>EM</sub> and liver T<sub>RM</sub> populations (Fig. 3c,d). By plotting their relative impact, we looked for genes that had a significant effect in reducing the accumulation of sg*Fdft1* while sparing control sg*Cd19* P14 T cells in memory populations, as these likely mediate the enhanced accumulation observed (Fig. 3d, Extended Data Fig. 6f, and Supplementary Table 8). Comparison to T<sub>E</sub> and T<sub>MP</sub> cells from day 7 of infection provided a reference for identifying genes that were required only at the memory timepoint rather than at the effector stage, such as *Ggpsi1* or *Trit1*. Genes that affected both populations equally, and thus fall in the plot's diagonal, do not likely mediate the specific advantage observed upon *Fdft1* deletion (Fig. 3d). This analysis revealed that several enzymes needed for CoQ synthesis (*Coq2*), geranylgeranylation (*Ggpsi1*) and tRNA modification (*Trit1*) showed a larger effect on *Fdft1* KO CD8 T cells than control CD8 T cells in spleen T<sub>EM</sub>, of which only *Coq2* was specific to memory cells (Fig. 3d). Further, the dependence on CoQ synthesis was more striking for the T<sub>RM</sub> population, as it included additional enzymes, such as *Hpd*, *Pdss1*, and *Pdss2* (Fig. 3d). Combined, these data revealed that the advantage endowed by *Fdft1* loss is supported by the production of non-steroidal metabolites, including CoQ (Extended Data Fig. 6g).

Given the critical role of *Pdss2* in our functional screens and its role in the first reaction producing CoQ from mevalonate products, we tested whether *Pdss2* overexpression could mediate enhanced  $T_{RM}$  formation. Indeed, enforced *Pdss2* expression led to a 3- to 8-fold increase in T cell accumulation compared to control vector across all tissues examined (Fig. 3e and Extended Data Fig. 6h). Of note, *Pdss2* OE restored SI  $T_{RM}$  formation to WT levels in mice fed a high cholesterol diet (Fig. 3f). Combined, these data suggest that  $T_{RM}$  increase *Srebp2* activity to meet a heightened requirement, particularly elevated in the SI, for non-steroidal products, such as CoQ. As such, promoting the accumulation of metabolic intermediates that can be diverted to CoQ production by blocking *Fdft1*, or boosting the capacity to shunt intermediates into the pathway by enforcing *Pdss2* overexpression, enhances  $T_{RM}$  formation and can offset some of the toxicities induced by an excess of dietary cholesterol. Of note, circulating memory CD8 T cell populations similarly benefitted from *Pdss2* OE (Fig. 3e), suggesting this pathway might generally increase T cell-mediated immunological memory.

## CoQ supports mitochondrial respiration

CoQ is a highly hydrophobic redox lipid in the inner mitochondrial membrane that transports electrons from complexes I and II to complex III in the electron transport chain (ETC). We next tested whether CoQ production driven by the mevalonate/cholesterol synthesis pathway impacted mitochondrial respiration. *Srebf2* KD CD8 T cells had lower rates of basal oxygen consumption (OCR) and reduced maximal respiration upon FCCP treatment (spare respiratory capacity, SRC) (Fig. 4a). Similarly, statin treatment reduced mitochondrial respiration of CD8 T cells in a mevalonate-dependent, but cholesterol-independent manner (Fig. 4b). A comparable loss of mitochondrial respiration was also observed in *Pdss2*-deficient CD8 T cells (Fig. 4c). Conversely, *Fdft1* deletion increased basal OCR and SRC (Fig. 4d), in a *Pdss2*-dependent manner (Fig. 4e). Of note, *Pdss2* OE was sufficient to promote higher basal and maximal mitochondrial respiration (Fig. 4f). In line with these data, deletion of *Fdft1* or enforced expression of *Pdss2*, lead to higher production of CoQ species, including the most abundant form in mice, CoQ9, and its precursor DMQ9 (Fig. 4f,g). Taken together, these data suggest that elevated rates of mevalonate/cholesterol synthesis intermediaries supply the CoQ pool to potentiate mitochondrial respiration in CD8 T cells.

Given the relationship between  $T_{RM}$  and  $T_{RM}$ -like TIL, including the importance of mitochondrial respiration and transcriptional programming<sup>17,37,38</sup>, we explored if common metabolic requirements might be shared between SI  $T_{RM}$  and functional TIL. To put our previous findings into the context of anti-tumor CD8 T cell responses, we performed scRNAseq profiling of P14 CD8 T cells responding to a murine tumor model (MC38-GP<sub>33-41</sub>). The mevalonate/cholesterol synthesis pathway was elevated in P14 CD8 TIL versus those in the spleen (Extended Data Fig. 7a,b). Examining the different subpopulations revealed that the proliferating (C4), terminally exhausted (C3), and  $T_{RM}$ -like TIL (C7) expressed the highest levels of *Srebp2*-dependent targets, enzymes *Hmgcs1* and *Hmgcr* (Extended Data Fig. 7c). Similarly, reanalysis of a human pan-tumor dataset revealed that the mevalonate/cholesterol pathway was most upregulated in proliferating, exhausted, effector, and  $T_{RM}$ -like populations (found mostly within the tumor) and low in memory and



naive CD8 T cell populations (found mostly in circulation) across 21 different cancer types<sup>39</sup> (Extended Data Fig. 7d). Thus, in both human and mouse, increased expression of genes involved in mevalonate/cholesterol synthesis in TIL implicate this pathway in intratumoral T cell accumulation.

## An Srebp2-CoQ axis boosts tumor immunity

To functionally test whether  $T_{RM}$  and TIL shared common metabolic adaptations related to the mevalonate/cholesterol synthesis pathway and to pin down which of its components were most relevant, we performed two *in vivo* CRISPR/Cas9 screens in P14 CD8 T cells in parallel using the 50-gene library targeting key elements of this pathway (Supplementary Table 5): one in the context of LCMV infection for the formation of SI  $T_{RM}$ , and the second in the context of MC38-GP<sub>33-41</sub> tumors for the accumulation of TIL (Fig. 5a). This experiment revealed a significant correlation between the impact of these genes on TIL and SI  $T_{RM}$  accumulation, with 19 significant genes commonly required for both cellular populations (67% overlap) (Fig. 5b,c, Extended Data Fig. 7e and Supplementary Table 9). Targeted genes were essential for T cells in the tumor and for  $T_{RM}$  but were largely dispensable for T cells in the draining lymph node (dLN) (Fig. 5b). Most of the 19 genes with a shared requirement by  $T_{RM}$  and TIL mediate the production of non-steroidal metabolites, including *Hpd* and *Coq2* that lead to CoQ production (Fig. 5c,d). As we observed for SI  $T_{RM}$ , these data showed that synthesis of cholesterol was not required for TIL accumulation (*Dhcr7* and *Dhcr24* were not essential) (Fig. 3a and Fig. 5c). Consistent with our studies in the context of infection, *Srebf2* deficiency impaired accumulation of P14 CD8 T cells in the tumor (Fig. 5e), loss of *Pdss2* reversed the increased accumulation of *Fdft1* KO P14 CD8 T cells in the tumor (Fig. 5f), and *Pdss2* OE promoted an even higher accumulation of P14 CD8 T cells in the tumor than in the spleen (Fig. 5g). Taken together, these data showed that both  $T_{RM}$  and TIL populations rely on a sustained and elevated Srebp2-driven program to synthesize non-steroidal metabolites, such as CoQ, to support their accumulation.

We next tested if it was possible to enhance T cell activity in tumors by enforcing the  $T_{RM}$  metabolic state. *Fdft1* deletion increased P14-dependent tumor control of MC38-GP<sub>33-41</sub> tumors, accompanied by improved P14 CD8 T cell persistence in tumors, dLN, and spleens (Fig. 5h,i). Similarly, *Pdss2* OE enhanced tumor control in B16-GP<sub>33-41</sub> melanoma tumors (Fig. 5j), and promoted a higher frequency of  $T_{RM}$ -like TIL (Fig. 5k). Of note, we did not find changes in the expression of exhaustion-associated markers or differences in cytokine production upon *ex vivo* restimulation (Extended Data Fig. 7g,h,i,j). Finally, *Fdft1* inhibition by administration of a competitive metabolite derived from fungi, Zaragozic Acid A (ZAA), reduced tumor growth and improved the survival of mice implanted with MC38-GP<sub>33-41</sub> tumors in a CD8-dependent manner (Extended Data Fig. 7k,l,m). These data are consistent with previous reports of the immune system-dependent effects on antitumor control of ZAA<sup>40</sup>. When combined with anti-PD1 treatment, ZAA led to greater control of B16-GP<sub>33-41</sub> melanoma tumors, further indicating that *Fdft1* may be a valid treatment target (Fig. 5l). Taken together, this study revealed that an understanding of the metabolic regulators of  $T_{RM}$  populations can be leveraged to improve CD8 T cell immunity against

infections and tumors, including avenues to increase the production of CoQ downstream of Srebp2 (Fig. 5m).

## Discussion

Combining functional screens of metabolic dependencies with transcriptomic and metabolomic profiling of circulating and resident subsets of memory CD8 T cells offered a systematic approach to identifying how metabolism impacts memory CD8 T cell formation in response to viral infections. In agreement with previous findings<sup>25,27</sup>, our results support the emerging concept that T<sub>RM</sub> formation requires distinct transcriptional and metabolic adaptations to different tissue environments. These data describing multiple potentially novel regulators of CD8 T cell memory differentiation have been made publicly available in a web-based application, Functional Immunometabolism and Transcriptomics Database (FITdb, fitdb.de).

Here, we chose to focus on SI T<sub>RM</sub> because these cells display profound metabolic differences from their circulating counterparts, maintain a controlled basal state of heightened activation resembling effector cells<sup>4</sup>, and possess molecular features associated with superior CD8 T cell functionality against tumors<sup>17,26</sup>. We found the Srebp2-dependent upregulation of the mevalonate/cholesterol synthesis pathway as the most distinguishable metabolic feature of SI T<sub>RM</sub>. Mechanistically, Srebp2 sustained transcriptional activation of the mevalonate/cholesterol biosynthesis pathway to support the production of non-steroidal products, including CoQ, which promoted mitochondrial respiration *in vitro* and *in vivo* accumulation in infection and tumors. We also showed that SI T<sub>RM</sub> respond to dietary cholesterol, which when in excess, was detrimental to their formation. Together, these adaptations might explain previous studies reporting an increase of mevalonate/cholesterol enzymes by T cell populations of the intestine<sup>4,41,42</sup>, and offer new insights into how dietary interventions could be leveraged to improve cellular immunity in the gastrointestinal tract<sup>36,43</sup>. Statins impact immune responses<sup>35</sup>, including reducing lymphocyte concentrations of CoQ<sup>44</sup>. Interestingly, our results highlight the dependency of SI T<sub>RM</sub> on this pathway and implicate a potentially significant effect in humans. Overall, our study identifies both dietary and pharmacological approaches to modulate T cell responses in the intestine.

Our data further reveal a common dependency on mevalonate/cholesterol synthesis enzymes for SI T<sub>RM</sub> formation and TIL accumulation. Based on these observations, we found two actionable enzymes, Fdft1 and Pdss2, which can be manipulated to enforce CoQ production, enhance the mitochondrial respiratory capacity of CD8 T cells, and promote *in vivo* accumulation of CD8 T cells in the context of infection and tumors. Whether these adaptations are conserved across all tumor types and contexts remains to be further investigated. The fact that loss of most genes of the mevalonate/cholesterol synthesis pathway impaired TIL accumulation in the melanoma model B16-OVA from a previous study<sup>28</sup> (Extended Data Fig. 8a), suggests these observations may be generalized to other tumor contexts.

$T_{RM}$ -like TIL, and cells genetically endowed with superior antitumor properties, such as Regnase 1 KO CD8 T cells<sup>28</sup>, upregulate the mevalonate/cholesterol synthesis pathway in the absence of increased proliferation (Extended Data Fig. 8b). Based on our data, and given that cholesterol accumulation in the tumor microenvironment leads to intracellular cholesterol buildup in TIL conducive to dysfunction<sup>45,46</sup>, we propose increased Srebp2-driven mevalonate/cholesterol pathway synthesis in TIL serves to generate non-steroidal metabolites, rather than cholesterol (Fig. 5m). Of note, deletion of genes leading to CoQ synthesis (ie *Pdss2*) were able to abolish the heightened antitumor potential of Regnase-1 KO T cells (Extended Data Fig. 8c)<sup>28</sup>. Certainly, the reliance on non-steroidal intermediates does not preclude the need for generating or obtaining sufficient cholesterol to support T cell functions during priming and activation in responses against pathogens and tumors. In sum, we provide conclusive evidence that  $T_{RM}$  utilize distinct metabolic adaptations, which can be exploited to enhance the function of CD8 T cells in solid tumors.

## Methods

### Mice

Mice were maintained in specific-pathogen-free conditions at a temperature between 18 °C and 23 °C with 40–60% humidity and a 12h-light and 12h-dark light cycle in accordance with the Institutional Animal Care and Use Committees (IACUC) of the University of California, San Diego (UCSD) and the University of California, Los Angeles (UCLA). All mice were of C57BL6/J background and bred at UCSD, UCLA or purchased from the Jackson Laboratory. P14, Cas9eGFP (stock #026179, The Jackson Laboratory), Thy1.1, and CD45.1 congenic mice were bred in house. Male and female mice were used for experiments, and were age and sex-matched, between 1.5 and 6 months old, and randomly assigned to experimental groups, except for therapeutic and dietary interventions where mice were randomly distributed into different experimental arms. No statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported in previous publications from our laboratory and others. No blinding was performed during mouse experiments. Investigators were not blinded to group allocation during data collection and/or analysis. Low (D12102C) and high (D12104C) cholesterol diets were procured from Research Diets<sup>51</sup>. Mice were fed ad libitum for the specified amount of time. Intravascular staining of CD8 T cells was done by administration of 3 µg of anti CD8α APC-eFluor780 (eBioscience 47–0081-82) in 200 µl of PBS by retroorbital (RO) route. CD8α<sup>+</sup> (IV<sup>-</sup>) cells were considered to be localized within non-lymphoid tissues<sup>52</sup>. Isolation of IV<sup>-</sup> P14 CD8 T cells from the liver may exclude resident T cells in the vasculature. All animal studies were approved by the Institutional Animal Care and Use Committees of the University of California, San Diego (UCSD) and performed in accordance with UC guidelines.

### Statistical methods

Statistical tests were performed using Prism (7.0/8.0/9.0) (Graphpad). Two-tailed paired or un-paired t-Test was used to compare groups with normally distributed values unless otherwise specified. Mann-Whitney U test was performed when value distributions did not pass normality tests. A Two-sided one-sample t-Test was used to compare data distributions against a hypothetical value of 0. Two-way ANOVA was used to test the effects of two

variables on a continuous outcome. Fisher's exact test was performed to determine the non-random association between two categorical variables. Logrank test was performed to test for differences between the populations in the probability of an event at any time point, related to survival analysis. P values of less than 0.05 were considered significant.

### Cell culture

PlatE cells were acquired from Cell Biolabs (RV-101). MC38-GP<sub>33-41</sub> cell line was generated from the commercially available C57BL/6 murine colon adenocarcinoma MC38 parental cell line (cat.# ENH204-FP, Kerafast). HEK293T cells were a gift from the Chi lab and originally sourced from the ATCC (CRL-3216). The B16-GP<sub>33-41</sub> cell line was a gift from Dr. Alain Lamarre and is derived from C57BL/6 murine B16-F10 skin melanoma. PlatE, MC38-GP<sub>33-41</sub>, and B16-GP<sub>33-41</sub> cells were cultured in DMEM + D-glucose supplemented with 10% bovine growth serum, 100 U/mL Penicillin, 100 µg/mL Streptomycin, 292 µg/mL L-glutamine, and 10 mM HEPES. Enriched CD8 T cells were maintained in RPMI + L-glutamine supplemented with 10% fetal bovine serum, 100 U/mL Penicillin, 100 µg/mL Streptomycin, 292 µg/mL L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate (Gibco), 1X MEM NEAA (Gibco), and 55 µM 2-Mercaptoethanol.

### Naive T cell transfers and infection models

$5 \times 10^4$  naive P14 CD8 T cells were transferred intravenously into congenically distinct sex-matched recipient mice, or female P14 cells were transferred into male mice. Recipient mice were subsequently infected intraperitoneally with  $2 \times 10^5$  plaque-forming units (PFU) of the Armstrong strain of LCMV or 5000 colony-forming units (CFU) of *L. monocytogenes* expressing GP<sub>33-41</sub> one day after cell transfer.

### Single transfer and co-transfer experiments of in vitro-activated and transduced P14 CD8 T cells

For transfections using retroviral constructs, PlatE cells were seeded in 10-cm dishes at a density of  $2.5 \times 10^5$  cells/plate 1 day before transfection in complete DMEM media (10% FBS, 2mM L-Glutamine, 1X Penicillin/Streptomycin). Transfections were performed with 25 µg plasmid DNA from each pLMPd-Amt, or LsgA clone with TransIT-LT1 (Mirus). Retroviral supernatant was harvested 48 h and 72 h after transfection. For transductions, negatively enriched naive CD8 T cells from spleen and lymph nodes were activated in 6-well plates coated with 100 µg/ml goat anti-hamster IgG (H+L; Thermo Fisher Scientific), 1 µg/ml anti-CD3 (145-2C11; eBioscience), and 1 µg/ml anti-CD28 (37.51; eBioscience). T cell culture media was removed 18 h after activation and replaced with retroviral supernatant supplemented with 50 µM β-mercaptoethanol (Gibco) and 8 µg/ml polybrene (Millipore) followed by a 1 h spinfection centrifugation at 2,000 rpm and 37°C. One day after transduction, congenically distinct ametrine<sup>+</sup> T cells were mixed 1:1 and  $5 \times 10^5$  total P14 cells were transferred into recipient mice subsequently infected with LCMV. Transduced CD8 T cell 1:1 ratios were validated by flow cytometry prior to adoptive cell transfer into mice.

### Preparation of single-cell suspensions for flow cytometry

Isolation of CD8 T cells was performed similarly as described<sup>5</sup>. SI IEL were prepared through the removal of Peyer's patches and the luminal contents from the entire SI. The SI was then cut longitudinally and into 1 cm pieces, then incubated at 37°C for 30 minutes in HBSS with 2.1 mg/mL sodium bicarbonate, 2.4 mg/mL HEPES, 8% bovine growth serum, and 0.154 mg/mL of dithioerithol (EMD Millipore). The kidneys, salivary glands, fat, liver, and tumors were minced into small pieces and then incubated in RPMI with 1.2 mg/mL HEPES, 292 µ/mL L-glutamine, 1 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 5% fetal bovine serum, and 100 U/mL collagenase (Worthington) at 37°C for 30 min. After enzymatic incubations (kidneys, WAT, and livers), tissues were further dissociated over a 70-µm nylon cell strainer (Falcon). Lymphocytes from the small intestine, kidney, salivary gland, and liver were separated on a 44%/67% Percoll density gradient. Spleens and lymph nodes were processed with the frosted ends of microscope slides. Red blood cells were lysed with ACK buffer (140 mM NH<sub>4</sub>Cl and 17 mM Tris-base, pH 7.4). Blood samples were treated with ACK lysis buffer.

### Antibodies, intracellular staining, flow cytometry and cell sorting

The following antibodies were obtained from TONBO: CD8a (53–6.7, FITC Catalog # 35–0081-U500, 1:200 dilution), Invitrogen: CD8a (53–6.7, PerCP-Cy5.5 Catalog # 1941169, PE Catalog # 2062469, PE-Cy7 Catalog # 25–0081-82, 1:200 dilution), PD1 (J43, APC Catalog # 47–9985-82, 1:200 dilution), CD127 (A7R34 PE Catalog # 12–1271-82, 1:50 dilution), Tim3 (RMT3, PE Catalog # 12–5870-82, 1:200 dilution), CD45.2 (104, PE-Cy7 Catalog # 25–0454-82, 1:200 dilution), KLRG1 (2F1 PerCP eF710 Catalog # 2011186, 1:400 dilution), and TNFα (MP6-XT22, APC Catalog # 17–7321-82, 1:100 dilution), eBioscience: CD3e (145–2C11 PE Catalog # 12–0031-83, 1:100 dilution), CD8β (H35–17.2 FITC Catalog # 11–0083-82, 1:200 dilution), CD11b (M1/70, PE Catalog # 12–0112-82, 1:400 dilution), CD45.1 (A20–1.7, APC Catalog # 17–0453-82, 1:200 dilution), Thy1.1 (HIS51, FITC Catalog # 11–0900-85, 1:1000 dilution), CD44 (IM7, APC Catalog # 17–0441-82, 1:400 dilution), and IL-2 (JES6–5H4, PE Catalog # 12–7021-82, dilution 1:50), BioLegend: CD8a (53–6.7, PB Catalog # 100725, 1:200 dilution), CD62L (MEL-14, BV421 Catalog # 104435, BV510 Catalog # 104441, 1:400 dilution), CD103 (2E7, PE-Cy7 Catalog # 121426, 1:200 dilution), B220 (RA3–6B2, BV711 Catalog # 103255, 1:200 dilution), CD44 (IM7, BV711 Catalog # 103057, BV510 Catalog # 103043, 1:400 dilution), CD69 (H1.2F3, BV711 Catalog # 104537, 1:100 dilution), CD45.1 (A20–1.7, BV786 Catalog # 110743, BV510 Catalog # 110741, 1:200 dilution), Thy1.1 (OX-7 BV421 Catalog # 202529, AF647 Catalog # 202508, 1:1000 dilution), and IFNγ (XMG1.2, Pacific Blue Catalog # 505818, 1:200 dilution), R&D Systems: LDLR (263123, FITC Catalog # 263123, PE Catalog # FAB2255P, 1:100 dilution), or BD Biosciences: CD107α (1D4B, FITC Catalog # 561069, 1:100 dilution). The H-2Db GP<sub>33–41</sub> tetramer was obtained from the NIH Tetramer Core conjugated to APC or BV421 fluorochromes and used at 1:200 dilution. Dead cell staining was performed with Fixable Viability Dye eFluor780 or eFluor506 (eBiosciences) and used at 1:2000 dilution. For flow cytometry analysis, all events were acquired on a BD LSRFortessa X-20 or a BD LSRFortessa running FACSDiva software v9.0. Cell sorting was performed on a BD FACSAria and flow cytometry analysis was performed on FlowJo v10.

## Imaging flow

Imaging flow cytometry data were acquired with a two-camera Amnis ImageStreamX MkII with 60X objective at Low speed using INSPIRE v6.2.187.0 acquisition software. 15,000 single, in-focus cells were collected per data file. FITC, PE, and PerCP were excited with a 488 nm laser (200 mW) and recorded in camera one. Filipin and BV510 were excited by a 405 nm laser (120 mW) and recorded in camera two. APC and APC-Cy7 were excited by 642 nm laser (150 mW) and recorded in camera two. SSC was recorded in channel 06 (camera one) and the 785 nm laser was set to 1.25 mW. Compensation was calculated with the IDEAS compensation wizard and then manually fine-tuned. Internal filipin intensities were calculated as a new feature on the Filipin channel using a mask based on M01 using Eroded 7 pixels with the IDEAS software. Feature intensities were exported as FCS files and further analyzed on FlowJo.

## LCMV rechallenge and quantification of LCMV titers by qPCR

LCMV rechallenge and quantification of LCMV titers by qPCR to measure protection was done as previously published<sup>24,53</sup>. In short, mice were infected IV with 5000 CFU of *L. monocytogenes* expressing GP<sub>33-41</sub>. 23 days after the primary challenge, mice were infected intraperitoneally with  $2 \times 10^5$  PFU of the Armstrong strain of LCMV. 3 days later, spleens and duodenum from the SI were harvested and flash-frozen in dry ice. RNA extraction from mice tissues was done following homogenization with mortar and pestle in liquid nitrogen, followed by homogenization with the QIAshredder (Qiagen), followed by RNA purification with the RNeasy kit (Qiagen). cDNA was generated by retrotranscribing 1  $\mu$ g of total RNA with random hexamer primers (High-Capacity cDNA Reverse Transcription Kit, Thermo Scientific). Quantification of LCMV genomes was performed by qPCR with 2x SYBR green (Agilent) and the following primers: m18S F (5'-3'): GTAACCCGTTGAACCCCAT, m18S R (5'-3'): CCATCCAATCGGTAGTAGCG, LCMV-GP F (5'-3'): CATTACCTGGACTTTGTCAGACTC, LCMV-GP R (5'-3'): GCAACTGCTGTGTTCCCGAAA, and LCMV-NP F (5'-3'): CAGAAATGTTGATGCTGGACTGC, LCMV-NP R (5'-3'): CAGACCTTGCTTGCTTTACACAG. The  $2^{-\Delta\Delta Ct}$  method, using m18S as housekeeping and WT samples as the reference group, was used to quantify the abundance of LCMV transcripts.

## Mitochondrial respiration analysis of CD8 T cells

Mouse CD8 T cells from the spleen were treated with vehicle or 10  $\mu$ M simvastatin (Sigma-Aldrich) at the time of activation in combination with 20  $\mu$ M of Methyl-beta-cyclodextrin (MBCD)-Cholesterol (Sigma) or 10  $\mu$ M mevalonolactone (Sigma) for 24 hours in complete T cell media. Analysis of in vitro activated and transduced CD8 T cells was performed 24 to 48 hours after transduction following FACS sorting of transduced cells. The Seahorse XF HS and XF96 Analyzers (Agilent) were used to measure the mitochondrial respiration capacity of CD8 T cells. Cells were seeded at a density of 20,000 cells per well in Seahorse XFp Cell Culture Miniplates with inserts without coating (Agilent Technologies) or 300,000 cells/well in CellTak-coated XF96 cell culture microplates (Agilent Technologies). Before seeding, cells were washed once with XF RPMI

(Agilent) complete media. Complete media contains freshly added 2 mM glutamine (Gibco), 1 mM Sodium Pyruvate (Gibco), and 10 mM glucose. For the statin experiment, DMEM (Sigma #D5030) supplemented with 8 mM glucose, 2 mM glutamine, 2 mM pyruvate, and 5 mM HEPES was used. Cells were plated in 160  $\mu$ l of volume, and plates were centrifuged at 300rcf for 4 minutes, followed by incubation at 37°C without CO<sub>2</sub> for 30 minutes to allow for cell attachment and equilibration. Next, the chemicals for the mitochondrial stress test were prepared in assay media and loaded into the cartridge. For the mitochondrial stress test, the following compounds were sequentially injected into each well: 1  $\mu$ M oligomycin, 2  $\mu$ M carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), or two rounds of 1  $\mu$ M FCCP injections, 0.5  $\mu$ M rotenone, and 0.5  $\mu$ M antimycin A (all from Agilent Technologies) and measurements were performed at 5-minute intervals. During the experiment, cells were maintained at 37°C without CO<sub>2</sub>. Three to six baseline measurements and three measurements following each injection were taken. Data were analyzed using the Seahorse XF Wave software (Agilent Technologies). Statistical analysis was performed using GraphPad Prism version 9.0 (GraphPad Software). Data were analyzed using a two-tailed paired t-test or a two-way ANOVA comparing OCR values by sample type and time.

### **Histology and Immunofluorescence staining of fresh frozen mouse tissues and FFPE human tissue**

Mouse organs were harvested and rapidly snap-frozen in OCT in plastic molds for cryosection (Tissue-Tek Cryomold). 10  $\mu$ m slices were obtained using a cryostat and mounted on glass slides, dried for 20 minutes at -20°C, submerged in cold PBS for 5 minutes and fixed in ice cold acetone at -20°C for 20 minutes. After fixation, slides were dried briefly at room temperature and stored at -80°C until stained. For staining, slides were equilibrated at room temperature, washed in PBS twice for five minutes, blocked in serum-free blocking reagent (Dako) ON at 4C, followed by staining with Srebp2 (ab30682, Abcam), CD103 PE (2E7, Invitrogen), CD45.2 FITC (104, Invitrogen) diluted in Antibody diluent solution (Dako) ON at 4 C, followed by a 2h incubation with Donkey Anti-Rabbit AF647 (Thermo Fisher), stained with DAPI, and mounted with coverslips using Vectashield hardset mounting media. Images were acquired on a Zeiss LSM700 confocal microscope and Aperio Scanscope at 20X and 63X resolution. Deidentified human FFPE samples from healthy subjects were acquired from NovusBio. Slides were treated according to standard immunohistochemistry procedures and stained with anti-HMGCR (LS-B16059, LSBio), anti-CD3e (ab11089, Abcam), and anti-CD8 $\alpha$  (66868, Thermo Fisher), followed by secondaries anti-rabbit AF647, anti-mouse AF488, and anti-rat AF594. Images were acquired at 20X with an Aperio FL fluorescence scanner system. Cell segmentation and quantification of HMGCR expression was done using Qupath<sup>54</sup>. In short, DAPI stains were used for cell detection with the following parameters; requestedPixelSizeMicrons 0.2, backgroundRadiusMicrons 2.5, sigmaMicrons 0.5, minAreaMicrons 5.0, maxAreaMicrons 50, threshold 300, waterShedPostProcess True, cellExpansionMicrons 1.5. CD8 $\alpha$  cells were identified by training an object classifier based on “Random trees” using CD8 $\alpha$ , and CD3e staining, as well as cell morphology features. HMGCR expression was obtained using compute intensity features on the ROI CD8 mask with tileSizeMicrons 10.0.

## Ultra-low input (ULI) RNA-sequencing

### **For studies pertaining to the profiling of shCd19 or shSrebf2 P14 CD8 T**

**cells:** for each replicate, cells from 2 mice were pooled and then sorted for ULI RNA-seq following Immgen guidelines. Seven, and 14 days after initial infection with LCMV,  $5 \times 10^3$  Ametrine<sup>+</sup> P14 cells from each congenic were sorted from the spleen, and  $5 \times 10^3$  iv<sup>-</sup> Ametrine<sup>+</sup> P14 cells were sorted from the IEL, kidney, and liver into PBS + 5% BSA + 2% FBS + 0.5 M EDTA.  $1 \times 10^3$  cells were then resorted into 5  $\mu$ l of 1x TCL lysis buffer + 1% 2-mercaptoethanol.

### **For studies pertaining to the profiling of SI T<sub>RM</sub> from mice fed low or high cholesterol-containing diets:**

Mouse previously infected (> 30 days) with LCMV and transferred with P14 CD8 T cells were fed a low or high cholesterol diet for 7 days. After preparation of single-cell suspensions,  $5 \times 10^3$  iv<sup>-</sup> P14 CD8 T cells were sorted from the IEL, into PBS + 5% BSA + 2% FBS + 0.5 M EDTA.  $1 \times 10^3$  cells were then resorted into 5  $\mu$ l of 1x TCL lysis buffer + 1% 2-mercaptoethanol. Library preparation for ULI RNA-seq was performed as described online at Immgen ("[ImmGenULI\\_RNaseq\\_methods.pdf](#)"). Trimmomatic was used to remove adapters and trim low-quality reads (NexteraPE-PE.fa:2:30:10:1:TRUE LEADING:3 TRAILING:3 SLIDINGWINDOW:4:15 MINLEN:25)<sup>55</sup>. Trimmed reads were then aligned to the gencode M25 annotation of the mm10 genome using STAR with the default conditions. Aligned reads were then quantified with featureCounts (-t exon -g gene\_id -p -B), and differentially expressed genes were identified using DESeq2<sup>56</sup>. GSEA was performed using the GSEA package in R<sup>57</sup>. When raw expression counts were used as input, kcdf was set to Poisson, otherwise kcdf was set to Gaussian.

## CRISPR-Cas9 mutagenesis screening using the lentiviral metabolic library

Lentiviral sgRNA metabolic library has been previously published<sup>23,28</sup>. In short, this custom mouse metabolic library contains 3,017 genes synthesized based on the gene list from reported human metabolic genes. A total of 6 gRNAs were designed for each gene according to previously published criteria. Two sub-libraries (Lib5 and Lib7) were made, with each containing 3 gRNAs targeting one gene and 500 non-targeting controls. The synthesis, purification, and quality control of the library was described previously. The in vivo screening approach was modified from previous studies. In short, lentivirus was produced by co-transfecting the lentiviral metabolic library plasmids, psPAX2, and pCAG4-Eco in HEK293T cells. At 48 h after transfection, the supernatant was harvested and frozen at -80°C. Naive P14 Cas9eGFP<sup>+</sup> were isolated and pooled from lymph nodes and spleens from 8 P14 Cas9eGFP mice followed by in vitro activation with plate-bound anti-CD3 (1  $\mu$ g/ml; 145-2C11; eBioscience) and anti-CD28 (1  $\mu$ g/ml; 37.51; eBioscience) antibodies for 24 hours. Immediately after, cells were spin infected by centrifugation with Lib5 and Lib7 library supernatants supplemented with 1:200 LentiBoost (Sirion Biotech) and 55  $\mu$ M beta-mercaptoethanol for 3h at 800G, followed by 4h incubation at 37°C 5% CO<sub>2</sub>. Immediately after, cells were washed and cultured with human IL-2 (20 IU/ml; Peprotech), mouse IL-7 (2.5 ng/ml; Peprotech) and IL-15 (25 ng/ml; Peprotech) for 4 days to expand and allow gene editing to occur. Next, cells were sorted based on the expression of Ametrine, and an aliquot of  $5 \times 10^6$  transduced Cas9eGFP P14 cells was saved as "input" (around  $500 \times$  cell



coverage per sgRNA). Transduced P14 cells ( $5 \times 10^5$ ) were then transferred IV to 7, and 9 naive C57BL/6 mice for Lib5 and Lib7, respectively, followed by LCMV infection ( $2 \times 10^5$  PFU) 1 h later. At day 13 and day 14 after LCMV infection for Lib 5 and Lib7, respectively, donor-derived TCM ( $CD62L^+CD127^+$ ),  $T_{EM}$ , and  $t-T_{EM}$  from the spleen,  $T_{EM}$  and  $T_{RM}$  from the liver, and  $T_{RM}$  from the SI were sorted into FBS and frozen at  $-80^\circ\text{C}$  until genomic DNA extraction. Cell coverage per sgRNA per population and library were: Lib5:  $T_{EM} = 110$ ,  $T_{CM} = 16$ ,  $t-T_{EM} = 66$ , Liver  $T_{EM} = 28$ , Liver  $T_{RM} = 8$ , SI  $T_{RM} = 12$ , and Lib7:  $T_{EM} = 141$ ,  $T_{CM} = 30$ ,  $t-T_{EM} = 77$ , Liver  $T_{EM} = 50$ , Liver  $T_{RM} = 17$ , Gut  $T_{RM} = 31$ .

### Targeted CRISPR Cas9 screen

sgRNAs targeting the 50 selected genes of the mevalonate and cholesterol synthesis pathway and adjacent enzymes were picked from either CRISPiCK or from the 3017 metabolic library and ordered as primers with BbsI overhangs from IDT as oPools Oligo Pools (IDT) and cloned into BbsI-linearized LsgA vector. Library preparation and equal sgRNA representation verification was done by subcloning into Stbl3 bacteria and sequencing of individual clones. Retroviral supernatant was titrated to achieve a targeted transduction efficiency of 30%, which is equivalent to an MOI of  $\sim 0.3$ . *sgCd19* and *sgFdf1* sgRNA were cloned into LMG retroviral plasmid. Double transduction of either LMG-*sgCd19* or LMG-*sgFdf1* with the targeted LsgA library was done via spinoculation of enriched and in vitro activated P14 Cas9eGFP T cells following by 24h expansion in hII-2 (10 u/mL). LMG-derived eGFP expression is two orders of magnitude stronger than eGFP on P14 T cells, thus making the identification of LMG-transduced P14 Cas9eGFP cells possible by flow cytometry. After sorting double positive ( $GFP^+Ame^+$ ) transduced P14 T cells,  $5 \times 10^5$  cells from either *sgCd19* and *sgFdf1* groups were transferred into 6 male B6 mice each and infected with LCMV 1 hour later. Cell pellets from double-transduced *sgCd19* and *sgFdf1* were kept as input. TE and TMP populations were sorted based on CD127 and KLRG1 stain from blood pooled from 6 mice of each condition at day 7 after infection and cell pellets were kept at  $-80^\circ\text{C}$ . Spleen  $T_{EM}$  and liver  $T_{RM}$  populations were sorted at day 14 after LCMV infection based on the expression of  $CD127^+$  and  $CD62L^-$  stain ( $T_{EM}$ ), and  $IV^-$  stain ( $T_{RM}$ ) of total P14 in the spleen, and liver, respectively, and pellets were stored at  $-80^\circ\text{C}$  until processing. The SI  $T_{RM}$  population included LP and IEL fractions and were similarly sorted at day 14 after LCMV infection by FACS. The dLN and TIL populations were sorted from single cell preparations from 5 pooled dLN and 5 pooled MC38-GP<sub>33-41</sub> tumors 6 days after adoptive cell transfer. The cell yields and cell per sgRNA coverage for each sample were as follows: Input *sgCd19*,  $1 \times 10^5$  total cells at 645 cells/sgRNA, Input *sgFdf1*,  $1 \times 10^5$  total cells at 645 cells/sgRNA, *sgCd19*  $T_E$ ,  $2.39 \times 10^5$  total cells at 1542 cells/sgRNA, *sgCd19*  $T_{MP}$ ,  $1 \times 10^4$  total cells at 65 cells/sgRNA, *sgCd19* Liver  $T_{RM}$ ,  $1 \times 10^4$  total cells at 65 cells/sgRNA, *sgCd19* Sp  $T_{EM}$ ,  $1 \times 10^4$  total cells at 65 cells/sgRNA, *sgFdf1*  $T_E$ ,  $1.6 \times 10^5$  total cells at 1032 cells/sgRNA, *sgFdf1*  $T_{MP}$ ,  $1 \times 10^4$  total cells at 65 cells/sgRNA, *sgFdf1* Liver  $T_{RM}$ ,  $6 \times 10^3$  total cells at 39 cells/sgRNA, and *sgFdf1* Sp  $T_{EM}$ :  $2.5 \times 10^3$  at 16 cells/sgRNA. The cell yields and cell per sgRNA coverage of the SI  $T_{RM}$  targeted screen were as follows: Input,  $1 \times 10^6$  cells at 645 cells/sgRNA, SI  $T_{RM}$ ,  $4.8 \times 10^3$  cells at 31 cells/sgRNA. The cell yields and cell per sgRNA coverage of the dLN and TIL screen in MC38-GP<sub>33-41</sub> were as follows: Input,  $5 \times 10^4$  total cells at 323 cells/sgRNA, dLN,  $3 \times 10^3$  total cells at 19 cells/sgRNA. TIL fractions were collected in two

subfractions: Tim3<sup>low</sup>, 4,425 cells at 29 cells/sgRNA, and Tim3<sup>high</sup>, 3,065 total cells at 20 cells/sgRNA. Frequency of Tim3<sup>high</sup> and Tim3<sup>low</sup> was ~50%. Fastq files from these two fractions were later combined to simplify analysis and increase coverage for TIL fraction. Genomic DNA was extracted according to the manufacturer's instructions (DNeasy, Qiagen), Qiagen). The sgRNA-containing LsgA cassette was amplified with LV primers forward 5' TTTCTTGGCTTTATATATCT 3' and reverse 5' GACTAGCCTTATTTTAACTT 3'. The PCR product was cleaned according to the manufacturer's instructions (QIAquick PCR purification), and Nextera handles were added by PCR using Nextera Handle forward 5' - TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTTTCTTGGCTTTATATATCT 3' and reverse 5' GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTAGCCTTATTTTAACTT 3'. After PCR product purification, PCR product was indexed with Illumina compatible indices. All PCR steps were done using proof-reading DNA polymerase Q5 (NEB). Library sizes were verified in the high sensitivity D1000 screen tape system (TapeStation, Agilent). Sequencing was performed in a Novaseq in a PE100 run format. sgRNA frequencies were obtained using MAGECK<sup>58</sup> count using the read 1 Fastq file and statistical testing against a background of six non-targeting sgRNAs using MAGECK -test of each sample output to its corresponding input. Only the verified sgRNA for *Srebf2* (Lib5\_20788.3: ACTCCAGTGACAGTACACTG) was used for analysis.

### Adoptive therapy tumor model

For adoptive therapy experiments,  $5 \times 10^5$  B16-GP<sub>33-41</sub> cells or MC38-GP<sub>33-41</sub>, which were verified Mycoplasma negative by PCR, and authenticated by in vitro killing assays, were transplanted subcutaneously into the right flank of wild-type B6 mice. After tumors became palpable, 7–8 days after transplantation, in vitro activated and expanded P14 CD8 T cells were transferred intravenously. For comparison of TIL accumulation in a mixed transfer setting, naive P14 CD8 T cells were activated, transduced and expanded with 50 U/mL of hIL-2 for 2–3 days; cells transduced with control constructs (*Cd19* shRNAmir) or experimental constructs (*Srebf2* shRNAmir) were mixed 1:1 and  $1 \times 10^6$  P14 cells were transferred intravenously. For efficacy studies, transduced cells were expanded for 5–6 days; transduced cells were then sorted, and  $1 \times 10^6$ – $2.5 \times 10^6$  cells were transferred intravenously into mice with established MC38-GP<sub>33-41</sub> or B16-GP<sub>33-41</sub> tumors. Tumors were monitored daily, and mice with ulcerated tumors or tumors exceeding 400 mm<sup>2</sup> were euthanized, in accordance with UCSD IACUC.

### Zaragozic Acid A (ZAA), anti-PD1 treatment, and CD8 depletion in mouse tumor models

At day 6 after tumor injection, the mice were randomized and treated every other day with ZAA (Santa Cruz Biotechnology) or vehicle control by alternating intravenous (200 µg/mouse) and intraperitoneal (100 µg/mouse) injections until day 16. For combination therapy with anti-PD1 antibody, ZAA was administered with the same schedule, and three consecutive treatments of anti-PD1 (InVivoMab anti-mouse PD-1 (CD279), BioXCell, BE0033–2) at 200 µg/mouse were delivered IP on days 9, 10, and 11 after tumor injection. Isotype control for Syrian IgG was used (InVivoMab polyclonal Syrian hamster IgG, BioXCell). For CD8-depleting experiments in combination with ZAA, anti-CD8α Ab (2.43 BioXCell) was administered intraperitoneally at a dose of 200 µg/mouse starting 2 days

prior to tumor implantation for three consecutive days (-2, -1, 0), followed by 2 additional doses of 100 µg/mouse on days 4 and 8, and ZAA treatment scheduled was started at day 4 after tumor implantation. Isotype control for Rat IgG2 was used (*In Vivo*MAB rat IgG2a isotype control, anti-trinitrophenol, BioXCell).

### Lovastatin treatment

2 days after LCMV Arm infection, mice were randomized into two groups and treated with either Vehicle (DMSO) or 10 mg/kg of Lovastatin (Calbiochem, 438185) in DMSO via IP injection daily for 5 consecutive days, followed by treatment once every three days after day 7 after LCMV infection until day 21 after LCMV infection.

### Cloning of mouse *Pdss2* CCDS in the pMIA vector

Total cDNA from liver homogenates of B6 WT mouse was used to PCR amplify *Pdss2* CCDS by using the primers F (5'-3'): TCTGAGGGTTTGAATCGCC, and R (5'-3'): CCGCCTCATTCTCTGGGTTT using a touch-down protocol starting at 62 with -0.5 C delta for 10 rounds, followed by 25 rounds of amplification at 58 C. PCR product was cleaned and reamplified with primers F (5'-3'): TAGCGGATCCCAATTGCTCGAGgccaccATGAGCCTCCGGCAGCTGCTGTTGCGCTTG and R (5'-3'): GGGCGGAATTGATCCCGCTCGAGTCAAGAAAATCTGGTCACAGCAAAC. This second set of primers adds complementary overhangs to the pMIA vector to allow cloning into Xho-I linearized pMIA plasmid using the NEBuilder HiFi DNA Assembly standard protocol (NEB), and add the Kozak sequence (gccacc) to promote gene expression. Cloned *Pdss2* gene sequence was verified by full plasmid sequencing (Primordium).

### shRNAmir sequences and sgRNA cloning in LsgA and LMG vectors

The following sequence was used for the shRNAmir targeting of *Srebf2* with the pLMPd-Amt retroviral construct: 5'-TGCTGTTGACAGTGAGCGATGCTCTAGAGTATTTGAAATATAGTGAAGCCACAGATGTATATTTCAAATACTCTAGAGCACTGCCTACTGCCTCGGA-3', and *Cd19* (control): 5'-TGCTGTTGACAGTGAGCGAATGGATAAGTCTGACGACCTATAGTGAAGCCACAGATGTATAGGTCGTGACACTTATCCATGTGCCTACTGCCTCGGA. Non-targeting (NT) shRNA (TRNSU6001), and shRNAmir targeting *Fdft1* (ULTRA-3215720) were purchased from Transomics. The following primer pairs used for CRISPR/Cas9-mediated gene disruption were hybridized by heating at 95°C for 5 minutes followed by a ramp down of 1°C each 30s to 4°C in UltraPure Distilled Water (Invitrogen):

sg*Cd19* forward 5'-CACCGACCTTCACGTGCCTCTCGA

sg*Cd19* reverse 5'-AAACTCGAGAGGCACGTGAAGGTC-3'

sg*Srebf2* (Lib5-20788.3) forward 5'-CACCGACTCCAGTGACAGTACACTG-3'

sg*Srebf2* (Lib5-20788.3) reverse 5'-AAACCAGTGTACTGTCACTGGAGTC-3'

sg*Fdft1* (Lib7–14137.1) forward 5'-CACCCCATCCCACACCCCATCCGG-3'

sg*Fdft1* (Lib7–14137.1) reverse 5'-AAACCCGGATGGGGTGTGGGATGG-3'

sg*Hpd* (Lib5–15445.3) forward 5'-CACCTGGAGATACCACACACACCC-3'

sg*Hpd* (Lib5–15445.3) reverse 5'-AAACGGGTGTGTGTGGTATCTCCA-3'

sg*Pdss2* (Lib5–71365.1) forward 5'-AAACATGATATTGGAATCTCGACC-3'

sg*Pdss2* (Lib5–71365.1) reverse 5'-AAACGGTCGAGATTCCAATATCAT-3'

Hybridized primer pairs were cloned into BbsI-linearized LsgA or LMG constructs by overnight ligation (T4 DNA Ligase, NEB) at room temperature, following transformation into DH5 $\alpha$  (ThermoFisher). In some instances, a "G" was added at the beginning of sgRNA sequences not naturally starting with a G to increase transcription efficiency.

### qPCR and sanger sequencing validation of gene targeting

For validation of *Srebf2*, *Fdft1*, *Pdss2* and *Hpd* gene targeting efficiencies with shRNAmir and sgRNA retroviral constructs, enriched CD8 T cells were activated, transduced, and expanded for 4–6 d in 25 mg/ml hIL-2 (Cetus). Ametrine<sup>+</sup> cells (*Srebf2* shRNAmir, *Srebf2* sgRNA, *Hpd* sgRNA, *Pdss2* sgRNA, *Fdft1* sgRNA, *Fdft1* shRNA, non-targeting shRNA, or control *Cd19* shRNAmir and sgRNA) were sorted directly into TRIzol (Life Technologies) for RNA quantification of shRNAmir knockdown, or MACS buffer with 2% FBS for genomic DNA isolation. RNA, and DNA were extracted per manufacturer specifications (RNeasy, Qiagen for RNA, DNeasy, Qiagen for genomic DNA). cDNA was then synthesized using Superscript II (Life Technologies) and quantitative PCR was performed using the Stratagene Brilliant II Syber Green master mix (Agilent Technologies). *Srebf2* and *Hmgcr* expression levels were normalized to the housekeeping genes *Hprt1*. The following primers were used for qPCR:

*Srebf2* forward: 5'-GCGTTCTGGAGACCATGGA-3'

*Srebf2* reverse 5'-ACAAAGTTGCTCTGAAAACAAATCA-3'

*Hmgcr* forward 5'-CTCGTGGAATGCCTTGTGATTG-3'

*Hmgcr* reverse 5'-AGCCGAAGCAGCACATGAT-3'

*Hmgcs1* forward 5'-GCCGTGAACTGGGTCGAA-3'

*Hmgcs1* reverse 5'-GCATATATAGCAATGTCTCCTGCAA-3'

*Ldlr* forward 5'-AGGCTGTGGGCTCCATAGG-3'

*Ldlr* reverse 5'-TGCGGTCCAGGGTCATCT-3'

*Hprt1* forward 5'-TGAAGAGCTACTGTAATGATCAGTCAAC-3'

*Hprt1* reverse: 5'-AGCAAGCTTGCAACCTTAACCA-3'

*Pdss2* forward: 5'-CACCATGATATTGGAATCTCGACC-3'

*Pdss2* reverse: 5'-AAACGGTCGAGATTCCAATATCAT-3'

*Fdft1* forward: 5'-GGATGTGACCTCCAAACAGGAC-3'

*Fdft1* reverse: 5'-CAGACCCATTGAGTTGGCACAC-3'

Targeting efficiency of sg*Srebf2*, sg*Fdft1*, sg*Pdss2*, and sg*Hpd* constructs on genomic DNA was assessed by PCR amplification of 100 ng of genomic DNA using a high-fidelity polymerase (Q5 High Fidelity DNA polymerase 2x, New England Biolabs) using a touchdown protocol (63°C T<sub>m</sub> -0.5 C/cycle for 10 cycles, followed by 25 cycles at 58°C). PCR products were purified according to the manufacturer's instructions (QIAquick PCR purification, Qiagen). Genomic DNA was amplified with the following primers:

*Srebf2* forward 5'-ATCATGGCTGTTCTGACTCGG-3'

*Srebf2* reverse 5'-GAAGCCATTTTTGCACAGGG-3'

*Fdft1* forward 5'-CTTCATGGGTCCTTGGGGAAC-3'

*Fdft1* reverse 5'-CCTGTGGGGCGTGTATTGTCA-3'

*Hpd* forward 5'-GCATCACAGTCTCCCATCCT-3'

*Hpd* reverse 5'-CTGTCTCACCTCCCGAAGTTT-3'

*Pdss2* forward 5'-TTGTCCCCTGCTACCATGTTC-3'

*Pdss2* reverse 5'-GAATGCCATGTCTTGGACCG-3'

Sanger sequencing of purified PCR products (Eton Biosciences) was done using the following primers:

*Fdft1* 5'-AACCATGAAGTGTGTCAT-3'

*Srebf2* 5'-AGCTGCTTTTCTGAAGGT

*Hpd* 5'-ACTACCGAGCAAAACGGCAG-3'

*Pdss2* 5'-GCCCTGTCTTCATGATGCCC-3'

Genome editing by CRISPR/Cas9 for each construct was calculated with TIDE<sup>59</sup>.

### Curation of metabolic signatures

We constructed a list of minimally overlapping metabolic gene sets (Metab205) by aggregating custom gene lists, and all gene sets from KEGG, BIOCARTA, and REACTOME listed in the C2.CP.gmt file from MsigDb (Broad Institute), and

iterating rounds of curation using the GSVA tool `computeGeneSetsOverlap` in R. To use Metab205 on mouse data sets, bulk microarray and RNAseq expression data sets were converted to human gene symbols using the GSEA Collapse Dataset tool with `Mouse_Gene_Symbol_Remapping_Human_Orthologs_MSigDb.chip` file with default options. For MAGECK analysis of pathway enrichments, and single cell RNAseq analysis, human Metab205 gene symbols were translated to mouse gene symbols using `bioDBnet`.

### scRNAseq of P14 in the subcutaneous MC38-GP<sub>33-41</sub> model

P14 from tumors and spleens of mice were profiled by scRNAseq in two independent repeats. For each repeat,  $2 \times 10^5$  P14 cells coming from pooled spleens and MC38-GP<sub>33-41</sub> tumors from three independent mice were sorted into T cell culture media. Samples were spun down at 500 rcf for 5 minutes and resuspended in PBS + 0.04% (w/v) bovine serum albumin. Samples were then loaded into Chromium Chip B (10X Genomics) and partitioned into Gel Bead In-Emulsions (GEMs) in a chromium controller (10X Genomics). Single cell RNA libraries were generated according to the Chromium Single Cell 3' Reagent Kits v3 User Guide and sequenced on a HiSeq 4000. Reads were aligned to the mm10 genome using `cellranger count` and final data matrices for all samples were generated with `cellranger aggregate`. The resulting counts matrix was then processed using Seurat in RStudio and cells with mitochondrial read % greater than 7 were discarded. Data was normalized and scaled using `NormalizeData` and `ScaleData` followed by batch correction of biological replicates was corrected with `Harmony`<sup>60</sup>. The top 2000 most variable genes were calculated using `FindVariableGenes` and used then used in the PCA calculation using `RunPCA`. After adding `Harmony` embeddings, we applied dimensionality reduction by `uMAP` using `harmony` reduction, and 1:20 dimensions. Louvain clustering was performed with Seurat's `FindClusters` based on the top 20 principal components with the resolution set to 0.5. Final gene expression values were normalized using `sctransform` in Seurat. Additionally, data imputation was performed using `MAGIC`<sup>61</sup> with the log-normalized expression values and the default settings and the exact solver. Seurat's `AddModuleScore` with default settings function was used to calculate scores for the mevalonate/cholesterol synthesis pathway gene list. Heatmap was generated by extracting average SCT gene expression values for each group, scaled gene expression values by row, and plotted with `ComplexHeatmap`<sup>62</sup>, installed from Bioconductor, with column clustering.

### Bioinformatic analysis of publicly available single-cell RNA-seq datasets

**Human single cell RNAseq of immune populations from PBMC, SI (Ileum) and colon of healthy patients:** Data were downloaded from GEO (GSE125527). Count matrices for each sample were acquired using `cellranger "count"` followed by `cellranger aggregate` to obtain a pooled data set. `Filtered_feature_bc_matrix` files were loaded into Seurat in RStudio to construct the Seurat object. Cells with `nCount` between 500 and 15000, and less than 25 % mitochondrial reads were retained. Gene expression was normalized with `SCTransform`, followed by standard Seurat clustering and dimensionality reduction steps with 40 dimensions and 0.8 resolution. CD8 T cells from healthy subjects were further subset using `SingleR`<sup>63</sup>. Imputation of gene expression was performed using `MAGIC`<sup>61</sup>. Core  $T_{RM}$  scores<sup>17</sup> were calculated with `UCell`<sup>64</sup> in CD8 T cells from the spleen and the SI, and values were tested for statistical significance between statin and non-statin users for

each tissue using the *ggsignif* package. The inclusion criteria for statin use included subjects who were actively taking statin medication at least two weeks before sampling.

### **Pan-cancer single-cell RNAseq atlas of tumor-infiltrating CD8 T**

**cells<sup>39</sup>**: integrated SingleCellExperiment .rds file (int.CD8.S35.sce.merged.rds) was retrieved from the Zenodo repository ([10.5281/zenodo.5461803](https://doi.org/10.5281/zenodo.5461803)) and transformed to a Seurat Object in R. Mevalonate/cholesterol synthesis pathway scores were calculated using AddModuleScore. The heatmap was generated with ComplexHeatmap with Euclidean distances to cluster rows (cancer type) and columns (meta.cluster.coarse). DimPlot was used to plot umap.harmony embeddings in a 2D plot grouped by “meta.cluster.coarse” annotations. Data from the CellTypist resource was downloaded from (<https://www.tissueimmunecellatlas.org/>) as an h5ad file, converted to a Seurat object, and mevalonate/cholesterol signature scores were calculated with UCell. DotPlot using the original metadata were used to plot scores grouped by different categories. The human signature for the mevalonate cholesterol synthesis pathway used was: *ACAT1, ACAT2, CYP51A1, EBP, FDFT1, FDPS, GGPS1, HMGCR, HMGCS1, HMGCS2, IDI1, LBR, LSS, MVD, MVK, PMVK, TM7SF2, DHCR7, DHCR24, NSDHL, HSD17B7, MSMO1, SC5DL, LOC651621, SQLE, LOC730412, IDI2*. (Note; The *SC5DL* gene name was updated to *SC5D* on June 1, 2020.)

### **In vivo Bodipy-Cholesterol, Bodipy-LDL uptake assays, and serum total cholesterol measurements**

200 µl of a 10 mg/ml of Bodipy-Cholesterol in corn oil (Sigma) solution (2mg Bodipy-Cholesterol) was orally gavaged into C57B6 mice. After 16 minutes, mice were iv labeled with CD8α antibody, and 4 minutes later mice were taken down for immune cell profiling by flow cytometry. Bodipy-Cholesterol incorporation into spleen CD8 T cells was used as a negative control. One mouse per experiment was orally gavaged with 200 µl of corn oil to establish baseline signal. 200 µl of 1 mg/ml of Human Bodipy-LDL (Invitrogen) was delivered IV by RO injection. After 26 minutes, mice were iv labeled with 3 µg of CD8α antibody, and 4 minutes later mice were taken down for immune cell profiling by flow cytometry. One mouse per experiment was RO injected with PBS to establish baseline signal. Cholesterol measurement in mouse serum was done using the Amplex Red Cholesterol Assay (Thermo Fischer) according to the manufacturer’s instructions. Mouse serum was collected by submandibular bleeding followed by centrifugation at 7000 rcf for 15 minutes at 4°C.

### **Intracellular Metabolite Isolation with Liquid chromatography-tandem mass spectrometry (LC-MS/MS) and analysis of metabolomics data.**

To assess relative steady-state variation between metabolic intermediates in tissue resident and peripheral T cell populations, freshly sorted populations were washed twice with ice-cold phosphate-buffered saline, centrifuged at low speed to avoid lysis, and stored without buffer at –80°C prior to analysis. Intracellular metabolite isolates were prepared as previously described<sup>65</sup>. Briefly, pelleted cells were lysed in a cold solution of 4:1 methanol:water and rapidly cycled between –80°C for one minute and 37°C for one minute, three times. Lysates were centrifuged at 14,000 RPM for 10 minutes at 4°C

to separate soluble metabolite extract from insoluble cell debris. Extracts were dried by vacuum concentrator and resuspended in a solution of cold 2:2:1 acetonitrile:methanol:water at 20,000 cell equivalents per microliter, and transferred to glass liquid chromatography vials for analysis. All solvents used were HPLC-grade (Fisher Scientific). Identification and quantification of extracted metabolites by LC-MS/MS analysis was described previously<sup>66</sup>. Sampling and liquid chromatography was performed on a Vanquish UHPLC system (Thermo Scientific) with Sequant ZIC-pHILIC polymeric column chromatography (100 mm × 2.1 mm, 5 μm) (EMD Millipore), maintained at 45°C. Cell extracts were separated by autosampler injection of 2 μL sample and eluting on a constant 0.4 mL/minute fluid flow rate. Elution followed a linear flow gradient of: (A) 20mM ammonium bicarbonate in water, pH 9.6, and (B) acetonitrile; 90% B for 0.25 minutes, a linear gradient to 55% B at 4 minutes, and maintained at 55% B until 6 minutes. Solid phase chromatography was then re-equilibrated for 2.5 minutes at 90% B between samples. Metabolite detection was performed via a coupled QExactive Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Scientific). Samples were eluted in duplicate for acquisition in positive and negative ionization mode. Ionization was by a heated electrospray ionization (HESI) source: spray voltage of 3.5 kV; auxiliary gas, sheath gas, and sweep gas flow rates of 20, 40, and 2 AU, respectively. Capillary gas heater temperature was 275°C and auxiliary gas heater temperature was 350°C. MS1 profile spectra were acquired in a mass range of 67–1000 m/z, with resolution of 35,000, AGC volume of 1×10<sup>6</sup> maximum IT of 75 ms. Data-dependent tandem mass spectra were acquired to aid in metabolite identification, using a normalized collision energy of 25 eV, an isolation window of 1.5 m/z, resolution of 17,500, a loop count of 5, AGC volume of 1×10<sup>5</sup>, and with maximum IT of 50 ms. Metabolite identifications were made against an in-house library of standards or against tandem spectral matching from publicly available databases housed in the GNPS Library ([gnps.ucsd.edu](http://gnps.ucsd.edu)) and meeting criteria for a match score of >0.70 and accurate mass window of 10 ppm. Tandem mass spectra matching against commercial standards of 4-hydroxybenzaldehyde (Millipore Sigma, 91554) and mevalonate (Millipore Sigma, 42147) were derived from the most abundant ion for each compound: m/z = 121.0295 for 4-hydroxybenzaldehyde [M-H], and m/z = 147.0663 for mevalonate [M-H]. Black spectra are derived from cell lysate, and red mirrored spectra from HPLC and GC-grade commercial standards. Intensity matrices for identified metabolites, or identified and annotated metabolites, were processed using Metaboanalyst 5.0 to perform clustered heatmaps and PCA.


### Quantification of CoQ species in CD8 T cells

Enriched, in-vitro-activated CD8 T cells with CD3/CD28, as previously described, were expanded in 50 U/mL of human IL-2 for 24 and treated with ZAA at 1 μM for 48h. Similarly, in-vitro-activated CD8 T cells were transduced with LsgA-sg*Cd19*, LsgA-sg*Fdft1*, pMIA-Empty, or pMIA-*Pdss2* constructs and expanded 48 h in 50 U/mL of human IL-2 before sorting 1–2×10<sup>6</sup> Ame<sup>+</sup> cells per sample. 1–2×10<sup>6</sup> cells were pelleted and frozen at –80°C until processing. Lipids were extracted using a modified version of the Bligh-Dyer method. Briefly, frozen cell pellets were resuspended in 350 μL of milliQ water shaken in an eppendorf tube with 300 μL methanol and 1 mL chloroform containing internal standards (d7-Cholesterol and d6-CoQ10) for 30s. The resulting mixture was vortexed for 15s and centrifuged at 2600 × g for 8 minutes to induce phase separation. The



organic (bottom) layer was retrieved using a Pasteur pipette, dried under a gentle stream of nitrogen, and reconstituted in 2:1 chloroform:methanol for LC/MS analysis. Lipidomic analysis was performed on a Vanquish HPLC online with a Q-Exactive quadrupole-orbitrap mass spectrometer equipped with an electrospray ion source (Thermo). Data was acquired in positive ionization mode. Solvent A consisted of 95:5 water:methanol, Solvent B was 70:25:5 isopropanol:methanol:water. Solvents A and B contained 5 mM ammonium formate with 0.1% formic acid. An XBridge (Waters) C8 column (5  $\mu$ m, 4.6 mm  $\times$  50 mm) was used for separation. The gradient was held at 0% B between 0 and 5 min, raised to 20% B at 5.1 min, increased linearly from 20% to 100% B between 5.1 and 55 min, held at 100% B between 55 minutes and 63 min, returned to 0% B at 63.1 min, and held at 0% B until 70 min. Flow rate was 0.1 mL/minute from 0 to 5 min, 0.3 mL/minute between 5.1 minutes and 55 minutes, and 0.4 mL/minute between 55 minute and 70 min. Spray voltage was 3.5 kV; S-lens RF level is 65; Sheath, auxiliary, and sweep gases were 50, 10 and 1, respectively. Capillary temperature was 325°C and auxiliary gas heater temperature was 200°C. Data was collected in full MS/dd-MS2 (top 10). Full MS was acquired from 150–1500 m/z with resolution of 70,000, AGC target of  $1 \times 10^6$  and a maximum injection time of 100 ms. MS2 was acquired with a resolution of 17,500, a fixed first mass of 50 m/z, AGC target of  $1 \times 10^5$  and a maximum injection time of 200 ms. Stepped normalized collision energies were 20, 30 and 40%. Skyline<sup>67</sup> was used to measure peak areas of a list of lipids of interest (CoQ9, CoQ10, DMQ9, DMQ10). Normalized peak areas were used in data reporting. Data were normalized using internal standards and total protein quantification.

## Extended Data



**Extended Data Figure 1. Functional genetics *in vivo*, metabolomics and transcriptional analysis of *ex vivo* populations of memory CD8 T cells identify a graded upregulation of a *Srebp2*-dependent metabolic programming across *TRM*.**

**a**, Unsupervised hierarchical clustering heatmap of scaled GSVA scores for metabolic signatures across samples, p.i., post-infection. GSE107278. **b**, sgRNA library heterogeneity reported as Gini Index values. **c**, Upset plot showing intersection sizes and set sizes for positive and negative regulators of each P14 CD8 T cell population in the *in vivo* CRISPR/


Cas9-mediated loss-of-function screen. **d**, Sample acquisition and analysis workflow for LC-MS/MS-based untargeted metabolomics of *ex vivo* populations of CD8 T cells in the context of LCMV infection. Gating strategy included for each cell type analyzed. **e**, Tandem mass spectra matching against commercial standards of mevalonate and mevalonolactone. Tandem mass spectra derived from the most abundant ion for each compound. Black spectra are derived from cell lysate, red mirrored spectra from commercial standard. **f**, Unsupervised hierarchical clustering of scaled relative abundances of identified annotated metabolites of P14 cells profiled by untargeted metabolomics at day 13 post LCMV infection.

Author Manuscript

Author Manuscript

Author Manuscript


Author Manuscript



**Extended Data Figure 2. Upregulation of the mevalonate/cholesterol synthesis pathway in mouse and human  $T_{RM}$ .**

**a**, Mevalonate/cholesterol synthesis GSVA scores from averaged single cell expression of spleen and SI P14 at indicated time points after LCMV infection profiled by scRNASeq, GSE131847. **b**, Mevalonate/cholesterol synthesis GSVA scores for indicated subsets of CD8 T cells in the spleen or SI in the context of LCMV infection, GSE157072. **c**, Mevalonate/cholesterol synthesis GSVA scores for indicated subsets of CD8 T cells at the indicated tissues in the context of LCMV and Herpes Simplex Virus (HSV), GSE70813. **d**, Gene


expression of indicated genes in P14 CD8 T cell populations from indicated tissues >30 days after LCMV infection, GSE182276 **e**, Mevalonate/cholesterol synthesis pathway scores for all human immune cells grouped by indicated tissues (left), cell types (middle), or cell types of the Jejunum SI (right), from the tissue immune cell scRNAseq atlas. **f**, Expression of selected genes on human CD8 T cells from PBMC, rectum, and SI samples, pooled from 13 healthy donors, GSE125527. **g**, HMGCR protein expression in CD8 T cells from human spleen, SI, and colon by immunofluorescence staining. Quantification of total HMGCR by CD8 T cell area. Donor ID (#). Scale bar, 20  $\mu$ m. **h**, GSEA of the mevalonate/cholesterol synthesis in Runx3 KO or control CD8 T cells GSE106107. Data are pseudo-bulk averaged values (**a**), mean  $\pm$  s.e.m. (**b**, **c**, and **d**), or geometric distribution (**f** and **g**), with a total of  $n=2$  (**b**),  $n=2-4$  (**c**),  $n=2-5$  (**d**) mice, and  $n=1-2$  (**g**) samples. Two-sided unpaired t-Test (**b**, **c**, **d**, **f**, and **g**), and Gene Set Enrichment Analysis (**h**). \* $P<0.05$ , \*\* $P<0.01$ , \*\*\* $P<0.005$ .



**Extended Data Figure 3. A Srebp2-dependent metabolic program controls SI TRM formation.**

**a**, Quantification of gene expression by qPCR of shRNA control (sh*Cd19*) or sh*Srebf2* shRNA P14 CD8 T cells before adoptive transfer. **b**, Frequency of effector shRNA control (sh*Cd19*) or sh*Srebf2* shRNA P14 CD8 T cell populations in the spleen 7 days after LCMV infection. **c**, Frequency of memory shRNA control (sh*Cd19*) or sh*Srebf2* shRNA P14 CD8 T cell populations in the spleen 21 days after LCMV

infection. **d**, CRISPR/Cas9-mediated indel efficiency of the *Srebf2* sgRNA construct on sorted transduced P14 cells before adoptive transfer. **e**, Frequency of effector sgCd19 or sg*Srebf2* P14 cell populations in the spleen 7 days after LCMV infection. **f**, Frequency of memory sgCd19 or sg*Srebf2* P14 cell populations in the spleen 21 days after LCMV infection. **g**, Total cell quantification of CD44<sup>high</sup> CD8 T cells (left) and Tet<sup>+</sup> CD8 T cells (right) in the blood of Scap WT or Scap KO at different time points after LCMV infection. **h**, Total cell quantification of Tet<sup>+</sup> CD8 T cells (upper) and CD44<sup>high</sup> CD8 T cells (lower) in SI, kidney, and liver of Scap WT or Scap KO at different time points after LCMV infection. **i**, Ratio of congenically distinct P14 CD8 T cells transduced with a constitutively active nuclear form of human Srebp2<sup>68</sup> (nSrebp2) or an empty vector (Empty) from indicated tissues 7 days after LCMV infection. **j**, Flow cytometry analysis of cholesterol content by Filipin stain (left), and LDLR expression in P14 CD8 T cells transduced with a bicistronic construct encoding Thy1.1 alone or Thy1.1 and nSrebp2 (right). P14 CD8 T cells from the kidney, liver, WAT, and SI were gated on the IV<sup>-</sup> population (**h** and **i**). Data are mean  $\pm$  s.e.m. and representative of at least two independent experiments, with a total of n=2 (**a**), n=4 (**b-e**), n=5 (**f**), n=6 (WT) and n=7 (Scap KO) (**g** and **h**), n=4 (**i** and **j**) mice and n=2 (**d**) cell replicates. Two-sided unpaired (**a**, **d**, **g**, and **h**) and paired (**j**) t-Test. \*P<0.05, \*\*P<0.01, \*\*\*P< 0.005. Two-sided one-sample t-Test (**i**) #P<0.05, ##P<0.01, ###P< 0.005. Two-way ANOVA (**h**) ##P<0.01.



#### Extended Figure 4. Limited effect of Srebp2 on transcriptional programs of CD8 T cell differentiation.

**a**, *Srebf2* expression values from the bulk ULI-RNAseq analysis of shRNA control (sh*Cd19*) and *Srebf2* shRNA P14 CD8 T cells from the spleen, kidney, liver, and SI from day 7 and 14 after LCMV infection. **b**, Mevalonate/cholesterol synthesis pathway GSVAs from the bulk ULI-RNAseq analysis of shRNA control (sh*Cd19*) and *Srebf2* shRNA P14 CD8 T cells from the spleen, kidney, liver, and SI from day 7 and 14 after LCMV infection. **c**, Unsupervised hierarchically clustered heatmap of mevalonate/cholesterol synthesis pathway gene expression values from the bulk ULI-RNAseq analysis of shRNA control (sh*Cd19*) and *Srebf2* shRNA P14 CD8 T cells from the spleen, kidney, liver, and SI from day 7 and 14 after LCMV infection. **d**, Core T<sub>RM</sub> GSVAs from the bulk ULI-RNAseq analysis of shRNA control (sh*Cd19*) and *Srebf2* shRNA P14 CD8 T cells from the spleen, kidney, liver, and SI from day 7 and 14 after LCMV infection. **e**, Circulating GSVAs from the bulk ULI-RNAseq analysis of shRNA control (sh*Cd19*) and *Srebf2* shRNA P14 CD8 T cells from the spleen, kidney, liver, and

SI from day 7 and 14 after LCMV infection. **f**, Volcano plots of differentially expressed genes between sh*Cd19* and sh*Srebf2* SI P14 CD8 T cells at days 7 and 14 after LCMV infection, adjusted (adj) p-value. P14 CD8 T cells from the kidney, liver and SI were gated on the IV<sup>-</sup> population (**a-f**). T<sub>E</sub> were defined as KLRG1<sup>high</sup>CD127<sup>low</sup> P14 CD8 T cells. Data are mean ± s.e.m.. (**a**, **b**, **d**, and **e**) from one experiment with n=2–3 (**a-f**), where every sample is 1×10<sup>3</sup> cells pooled from 2~3 mice. Two-sided unpaired t-Test (**a**, **b**, **d**, and **e**), and Deseq2 DEG testing with Benjamini-Hochberg multiple test correction. \*P<0.05, \*\*P<0.01, \*\*\*P< 0.005.


Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript






**Extended Data Figure 5. SI TRM uptake and sense dietary cholesterol.**

**a**, Quantification by flow cytometry of in vivo incorporation of Bodipy-cholesterol on indicated cell populations after 10 minutes after oral administration of Bodipy-cholesterol to memory P14 mice. **b**, Quantification by flow cytometry of incorporation of Bodipy-LDL on indicated cell types of the spleen 20 minutes (min) after IV delivery to memory P14 mice. **c**, Quantification of intracellular cholesterol by filipin staining in Tet<sup>+</sup> populations of CD8 T cells for various tissues >30 days post LCMV infection measured by imaging flow cytometry. **d**, Gene expression analysis by qPCR of selected Srebp2 targets on CD8 T cells


from the spleen and SI of mice on regular chow or subjected to low and high cholesterol-containing diets. **e**, Experimental design to measure transcriptional changes induced by dietary cholesterol on established SI T<sub>RM</sub> by ULI-RNAseq, **f**, SI T<sub>RM</sub> frequencies from total CD8 T cells after 7 days of dietary intervention. **g**, Food consumption per day per mouse subjected to a low or high-cholesterol diet. **h**, Bodyweight of mice subjected to low or high cholesterol-containing diets. **i**, Total cholesterol in serum in mice subjected to low or high cholesterol-containing diets. **j**, Volcano plot of differentially expressed genes in SI T<sub>RM</sub> from mice fed a high vs a low cholesterol-containing diet. **k**, Mevalonate/cholesterol synthesis GSVA scores in SI T<sub>RM</sub> from mice fed a high versus low cholesterol-containing diet. **l**, Gene pathway analysis of top upregulated and top downregulated genes between SI T<sub>RM</sub> from mice fed a high versus low cholesterol-containing diet (MsigDb, Hallmark gene sets). P14 CD8 T cells and CD8 $\beta^+$ /CD44<sup>high</sup>/Tet<sup>+</sup> from the kidney, liver and SI were gated on the IV<sup>-</sup> population (**a**, **b**, **c**, **e**, **f**, **j**, **k**, and **l**). Data are mean  $\pm$  s.e.m. and representative of at least two independent experiments, with a total of n=4 (**a**), n=3 (**b**, **d**), n=5 (**c**), n=3 (**f**) mice, or pooled from at least two independent experiments with a total of n=5–10 (**g-i**) mice, or performed once (**j-l**) with a total of n=3 samples each sample is  $1 \times 10^3$  SI T<sub>RM</sub> pooled from 2~3 mice (**j**, **k**). Two-sided unpaired t-Test (**a**, **b**, **d**, **f**, **i**, and **k**), and Deseq2 DEG testing with Benjamini-Hochberg multiple test correction (**j**). \*P<0.05, \*\*P<0.01, \*\*\*P< 0.005.



### Extended Data Figure 6. Mevalonate/cholesterol synthesis pathway intermediates sustain the production of non-steroidal metabolites.

**a**, The mevalonate/cholesterol synthesis pathway with adjacent and downstream metabolic routes. Enzymes not included in the first CRISPR/Cas9-mediated loss-of-function screen in grey, downstream products and/or fates of cholesterol are boxed, key measured metabolites in bold, non-steroidal metabolites in blue, key enzymes are bold and colored by in vivo effect of deletion in P14 CD8 T cells, gain-of-function in red, loss-of-function in blue, dashed lines indicate indirect or unknown mode of regulation. **b**, Abundance of 4-hydroxybenzaldehyde profiled by LC-MS/MS of *ex vivo* populations of P14 cells 13 days after LCMV infection. **c**, Tandem mass spectra matching against commercial standards of 4-hydroxybenzaldehyde. Tandem mass spectra derived from the most abundant ion for each compound:  $m/z = 121.0295$  for 4-hydroxybenzaldehyde [M-H], black spectra are derived from cell lysate, red mirrored spectra from commercial standard. **d**, CRISPR/Cas9-mediated indel efficiency of the *Hpd* sgRNA construct on sorted transduced P14 cells before adoptive transfer. **e**, CRISPR/Cas9-mediated indel efficiency of the *Fdf1* sgRNA construct on sorted transduced P14 CD8 T cells before adoptive transfer. **f**, Gini index scores of sgRNA representation in each library. **g**, Schematic illustration of the contribution of mevalonate/cholesterol pathway intermediates to non-steroidal products. **h**, Quantification of *Pdss2* mRNA by qPCR in transduced Empty and *Pdss2* OE P14 CD8 T cells. Data are mean  $\pm$  SE.


s.e.m. (**b** and **h**), and representative of at least two independent experiments (**d**, **e**, and **h**), with a total of n=2 (**d**, **e**), and n = 3 (**h**) cell replicates, or one experiment (**b**), with n=3 (SI), n=4 (T<sub>N</sub>), and n=5 (rest) (**b**) samples, where each sample contains cells pooled from 2 to 5 mice. Two-sided unpaired t-Test (**b**, **d**, **e** and **h**). \*P<0.05, \*\*P<0.01, \*\*\*P< 0.005.



**Extended Data Figure 7. Increased production of non-steroidal products of the mevalonate/cholesterol synthesis pathway is a common requirement between SI T<sub>RM</sub> and TIL.**

**a**, Dimensionality reduction plot by UMAP of P14 CD8 T cells profiled from spleens and subcutaneously implanted MC38-GP<sub>33-41</sub> tumors by scRNAseq 7 days after ACT.

**b**, Mevalonate/cholesterol synthesis signature values and expression of indicated genes in P14 CD8 T cells from the spleen and MC38-GP<sub>33-41</sub> tumors profiled by scRNAseq. MAGIC-imputed gene values are shown. **c**, Hierarchically clustered heatmap of scaled averaged gene expression values by cluster of P14 cells profiled from spleens and MC38-GP<sub>33-41</sub> tumors by scRNAseq 7 days after adoptive transfer. **d**, Dimensionality reduction plot by UMAP of CD8 T cell metaclusters (left) with “meta.cluster.coarse” labels and hierarchically clustered heatmap of mevalonate/cholesterol synthesis pathway scores grouped by “meta.cluster.coarse” labels and cell type. NPC, nasopharyngeal carcinoma, ESCA, esophageal cancer, LC, lung cancer, HCC, hepatocellular carcinoma, CHOL, cholangiocarcinoma, RC, renal carcinoma, CRC, colorectal cancer, AML, acute myeloid leukemia, BCL, B-cell lymphoma, MM, multiple myeloma, HNSCC, head and neck squamous cell carcinoma, THCA, thyroid carcinoma, MELA, melanoma, BCC, basal cell carcinoma, SCC, squamous cell carcinoma, BRCA, breast cancer, STAD, stomach adenocarcinoma, PACA, pancreatic cancer, OV, ovarian cancer, FTC, fallopian tube carcinoma, UCEC, uterine corpus endometrial carcinoma. EMRA, effector memory CD45RA<sup>+</sup>, mem, memory. **e**, sgRNA library heterogeneity reported as Gini Index values. **f**, CRISPR/Cas9-mediated indel efficiency of the *Pdss2* sgRNA construct on sorted transduced P14 CD8 T cells. **g**, Frequency of PD1<sup>high</sup>Tim3<sup>high</sup> and PD1<sup>high</sup>Tim3<sup>low</sup> subpopulations for sg*Cd19* and sg*Fdft1* Cas9 P14 CD8 T cells in MC38-GP<sub>33-41</sub> tumors at day 5–7 after adoptive transfer. **h**, Frequency of PD1<sup>high</sup>Tim3<sup>high</sup> and PD1<sup>high</sup>Tim3<sup>low</sup> subpopulations for Empty and *Pdss2* OE P14 CD8 T cells in MC38-GP<sub>33-41</sub> tumors at day 5–7 after adoptive transfer. **i**, Quantification of gene expression by qPCR of control (sh*NT*) and *Fdft1* deficient (sh*Fdft1*) P14 CD8 T cells before adoptive transfer. **j**, Restimulation capacity of control (sh*NT*) and *Fdft1* deficient (sh*Fdft1*) P14 TIL 4 days after *in vivo* transfer treated with GP<sub>33-41</sub> peptide *ex vivo*. **k**, MC38-GP<sub>33-41</sub> tumor growth curves of mice receiving ZAA or vehicle. **l**, Survival of mice implanted with MC38-GP<sub>33-41</sub> tumors receiving ZAA or vehicle. **m**, MC38-GP<sub>33-41</sub> tumor growth curves of mice receiving ZAA in combination with CD8 T cell depletion. Data are mean ± s.e.m.. (**g**, **h**, **i**, **j**, **k**, and **m**), raw values (**d**), geometrical distributions of single-cell gene expression values (**b**) or averaged gene expression (**c** and **e**) and pooled or representative of at least two independent experiments, with a total of n=2 (**f**) cell replicates, and n=8 (**g**), n=9 (**h**), n=3 (**i**), n=10 (**j**), n=12/group (**k**, **l**), n=5/group (**m**) mice. Two-sided unpaired t-Test (**b**, **f** and **i**). Log-rank test (**l**). Two-way ANOVA (**m**). \*P<0.05, \*\*P<0.01, \*\*\*P< 0.005.



### Extended Data Figure 8. A requirement for the mevalonate/cholesterol synthesis enzymes for TIL persistence and heightened antitumor activity in a melanoma model.

**a.** GSEA of the mevalonate/cholesterol synthesis pathway in genes pre-ranked by their impact on TIL accumulation in B16-OVA tumors from a published CRISPR/Cas9-mediated loss-of-function screen. **b.** Dimensionality reduction plot by UMAP of WT and Regnase-1 KO OT-I cells profiled from MC38-GP<sub>33-41</sub> tumors by scRNAseq 7 days after adoptive transfer (left) and unsupervised hierarchical clustering heatmap of selected genes related to CD8 T cell cytotoxicity (*Ifng*) stemness (*Tcf7*), proliferation (*Mki67*), and the mevalonate/cholesterol synthesis pathway (*Srebf2*, *Hmgcs1*, *Fdft1*, *Hmgcr*, and *Ldlr*) grouped by cell type and cluster. **c.** Comparison of the effect of targeting the 50 genes of the mevalonate/cholesterol pathway included in our targeted screen in WT TIL or Regnase-1 KO TIL (*sgZc3h12a*) from a published CRISPR/Cas9-mediated loss-of-function screen in B16 melanoma tumors<sup>32</sup>. Relevant enzymes are labeled.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank Dr. Matthew Pipkin for generously sharing the shSrebf2 plasmid, Dr. Andrea Reboldi for generously sharing the nSrebp2 OE plasmid, Dr. Shane Crotty and Dr. Katia Faliti for generously sharing the LsgA vector backbone, and Guillermina Garcia and Monica Sevilla for technical histological assistance. We also thank the Center for Advanced Technology at UCSF for sequencing support, Dr. Lara Labarta-Bajo and the Goldrath laboratory members for technical advice, helpful discussion and critical reading of the manuscript, and the Immunological Genome Project (ImmGen) for reagents and sample/data processing. We thank Dr. Antonio M. Pinto and the Mass Spectrometry Core of the Salk Institute with funding from NIH-NCI CCSG: P30 014195 and the Helmsley Center for Genomic Medicine. The MS data described here were gathered on a ThermoFisher Q Exactive Hybrid Quadrupole Orbitrap mass spectrometer funded by NIH grant (1S10OD021815-01).

## Funding

National Institutes of Health grant R01 AI067545 (AG)

National Institutes of Health grant P01 AI132122 (AG)

National Institutes of Health grant R01 AI150282 (AG)  
 National Institutes of Health grant R01 AI072117 (AG)  
 National Institutes of Health grant R01 CA197363 (MK)  
 National Institutes of Health grant P01 HL146358 (SJB)  
 National Institutes of Health grant R01 HL157710 (SJB)  
 Cancer Research Institute Postdoctoral Fellowship CRI2943 (MR-C)  
 Cancer Research Institute Postdoctoral Fellowship CRI4145 (GG)  
 HHMI fellowship GT14887 (KTK)  
 NCI grant P30 CA030199 (SBP Flow Cytometry Core)  
 NIH grant P30 DK063720 (UCSF Parnassus Flow CoLab)  
 National Institutes of Health SIG grant S10 OD026929 (UCSD IGM Core)

## Data and materials availability

Bulk RNA-seq, and single-cell RNA-seq have been deposited to GEO under the reference series GSE207044. In addition, the following published datasets were used: GSE107278<sup>17</sup>, GSE106107<sup>17</sup>, GSE182276<sup>24</sup>, GSE70813<sup>47</sup>, GSE157072<sup>48</sup>, GSE125527<sup>49</sup>, GSE131847<sup>48</sup>, GSE137015<sup>28</sup>, GSE70813<sup>47</sup>, and GSE157072<sup>50</sup>.

## References

- Masopust D & Soerens AG Tissue-Resident T Cells and Other Resident Leukocytes. *Annu Rev Immunol* (2019) doi:10.1146/annurev-immunol-042617-053214.
- Park SL, Gebhardt T & Mackay LK Tissue-Resident Memory T Cells in Cancer Immunosurveillance. *Trends Immunol* 40, 735–747 (2019). [PubMed: 31255505]
- Byrne A et al. Tissue-resident memory T cells in breast cancer control and immunotherapy responses. *Nature Reviews Clinical Oncology Preprint* at 10.1038/s41571-020-0333-y (2020).
- Konjar Š et al. Mitochondria maintain controlled activation state of epithelial-resident T lymphocytes. *Sci Immunol* 3, 2543 (2018).
- Steinert EM et al. Quantifying Memory CD8 T Cells Reveals Regionalization of Immunosurveillance. *Cell* 161, 737–749 (2015). [PubMed: 25957682]
- Wijeyesinghe S et al. Expansile residence decentralizes immune homeostasis. *Nature* 592, 457–462 (2021). [PubMed: 33731934]
- Soerens AG et al. Functional T cells are capable of supernumerary cell division and longevity. | *Nature* | 614, (2023).
- Gebhardt T et al. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. *Nature Immunology* 2009 10:5 10, 524–530 (2009).
- Iijima N & Iwasaki A A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells. *Science* (1979) 346, 93–98 (2014).
- Jiang X et al. Skin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity. *Nature* 2012 483:7388 483, 227–231 (2012).
- Teijaro JR et al. Cutting Edge: Tissue-Retentive Lung Memory CD4 T Cells Mediate Optimal Protection to Respiratory Virus Infection. *The Journal of Immunology* 187, 5510–5514 (2011). [PubMed: 22058417]
- Ariotti S et al. Skin-resident memory CD8+ T cells trigger a state of tissue-wide pathogen alert. *Science* (1979) 346, 101–105 (2014).

13. Schenkel JM et al. Resident memory CD8 t cells trigger protective innate and adaptive immune responses. *Science* (1979) 346, 98–101 (2014).
14. Mackay LK et al. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. *Proc Natl Acad Sci U S A* 109, 7037–7042 (2012). [PubMed: 22509047]
15. Shin H & Iwasaki A A vaccine strategy that protects against genital herpes by establishing local memory T cells. *Nature* 2012 491:7424 491, 463–467 (2012).
16. Wu T et al. Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. *J Leukoc Biol* 95, 215–224 (2014). [PubMed: 24006506]
17. Milner JJ et al. Runx3 programs CD8 + T cell residency in non-lymphoid tissues and tumours. *Nature* 552, 253–257 (2017). [PubMed: 29211713]
18. Nizard M et al. Induction of resident memory T cells enhances the efficacy of cancer vaccine. *Nature Communications* 2017 8:1 8, 1–11 (2017).
19. Malik BT et al. Resident memory T cells in the skin mediate durable immunity to melanoma. *Sci Immunol* 2, 6346 (2017).
20. Ganesan AP et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. *Nature Immunology* 2017 18:8 18, 940–950 (2017).
21. Djenidi F et al. CD8 + CD103 + Tumor-Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients. *The Journal of Immunology* 194, 3475–3486 (2015). [PubMed: 25725111]
22. Reina-Campos M, Scharping NE & Goldrath AW CD8<sup>+</sup> T cell metabolism in infection and cancer. *Nat Rev Immunol* 21, (2021).
23. Huang H et al. In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8 + T cell fate decisions. *Cell* 184, 1245–1261.e21 (2021). [PubMed: 33636132]
24. Crowl J et al. Tissue-resident memory CD8+ T cells possess unique transcriptional, epigenetic and functional adaptations to different tissue environments. *Nat Immunol* (2022).
25. Pan Y et al. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. *Nature* 543, 252–256 (2017). [PubMed: 28219080]
26. Milner JJ & Goldrath AW Transcriptional programming of tissue-resident memory CD8+ T cells. *Curr Opin Immunol* 51, 162–169 (2018). [PubMed: 29621697]
27. Frizzell H et al. Organ-specific isoform selection of fatty acid-binding proteins in tissue-resident lymphocytes. *Sci Immunol* 5, 9283 (2020).
28. Wei J et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. *Nature* 576, 471–476 (2019). [PubMed: 31827283]
29. Locke FL, Zha Y, Zheng Y, Driessens G & Gajewski TF Conditional deletion of PTEN in peripheral T cells augments TCR-mediated activation but does not abrogate CD28 dependency or prevent anergy induction. *J Immunol* 191, 1677 (2013). [PubMed: 23851688]
30. Pauls SD & Marshall AJ Regulation of immune cell signaling by SHIP1: A phosphatase, scaffold protein, and potential therapeutic target. *Eur J Immunol* 47, 932–945 (2017). [PubMed: 28480512]
31. Kidani Y et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. *Nat Immunol* 14, 489–499 (2013). [PubMed: 23563690]
32. Yu B et al. Epigenetic landscapes reveal transcription factors that regulate CD8 + T cell differentiation. *Nat Immunol* 18, (2017).
33. Fernandez-Ruiz D et al. Liver-Resident Memory CD8+ T Cells Form a Front-Line Defense against Malaria Liver-Stage Infection. *Immunity* 45, 889–902 (2016). [PubMed: 27692609]
34. Shimano H & Sato R SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. *Nat Rev Endocrinol* 13, 710–730 (2017). [PubMed: 28849786]
35. Zeiser R Immune modulatory effects of statins. *Immunology* 154, 69–75 (2018). [PubMed: 29392731]
36. Sullivan ZA et al.  $\gamma\delta$  T cells regulate the intestinal response to nutrient sensing. *Science* (1979) 371, (2021).




37. Menk AV et al. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. *Journal of Experimental Medicine* 215, (2018).
38. Scharping NE et al. The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. *Immunity* (2016) doi:10.1016/j.immuni.2016.07.009.
39. Zheng L et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. *Science* (1979) 374, (2021).
40. Lanterna C et al. The administration of drugs inhibiting cholesterol/oxysterol synthesis is safe and increases the efficacy of immunotherapeutic regimens in tumor-bearing mice. *Cancer Immunol Immunother* 65, 1303–1315 (2016). [PubMed: 27520505]
41. Shires J, Theodoridis E & Hayday AC Biological Insights into TCR $\gamma\delta$ + and TCR $\alpha\beta$ + Intraepithelial Lymphocytes Provided by Serial Analysis of Gene Expression (SAGE). *Immunity* 15, 419–434 (2001). [PubMed: 11567632]
42. Fahrner AM et al. Attributes of  $\gamma\delta$  intraepithelial lymphocytes as suggested by their transcriptional profile. *Proc Natl Acad Sci U S A* 98, 10261–10266 (2001). [PubMed: 11526237]
43. Hoytema van Konijnenburg DP et al. Intestinal Epithelial and Intraepithelial T Cell Crosstalk Mediates a Dynamic Response to Infection. *Cell* 171, 783–794.e13 (2017). [PubMed: 28942917]
44. Passi S, Stancato A, Aleo E, Dmitrieva A & Littarru GP Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. *BioFactors* 18, 113–124 (2003). [PubMed: 14695926]
45. Xu S et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8 + T cells in tumors. *Immunity* 54, 1561–1577.e7 (2021). [PubMed: 34102100]
46. Ma X et al. Cholesterol Induces CD8(+) T Cell Exhaustion in the Tumor Microenvironment. *Cell Metab* 30, 143–156.e5 (2019). [PubMed: 31031094]
47. Mackay LK et al. Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes. *Science* 352, 459–463 (2016). [PubMed: 27102484]
48. Kurd NS et al. Early precursors and molecular determinants of tissue-resident memory CD8 + T lymphocytes revealed by single-cell RNA sequencing. *Sci Immunol* 5, (2020).
49. Boland BS et al. Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. *Sci Immunol* 5, (2020).
50. Milner JJ et al. Delineation of a molecularly distinct terminally differentiated memory CD8 T cell population. *Proc Natl Acad Sci U S A* 117, 25667–25678 (2020). [PubMed: 32978300]

## Methods References

51. O'Connor A, Quizon PM, Albright JE, Lin FT & Bennett BJ Responsiveness of cardiometabolic-related microbiota to diet is influenced by host genetics. *Mamm Genome* 25, 583–599 (2014). [PubMed: 25159725]
52. Anderson KG et al. Intravascular staining for discrimination of vascular and tissue leukocytes. *Nature Protocols* 2013 9:1 9, 209–222 (2014).
53. McCausland MM & Crotty S Quantitative PCR technique for detecting lymphocytic choriomeningitis virus in vivo. *J Virol Methods* 147, 167–176 (2008). [PubMed: 17920702]
54. Bankhead P et al. QuPath: Open source software for digital pathology image analysis. *Scientific Reports* 2017 7:1 7, 1–7 (2017).
55. Bolger AM, Lohse M & Usadel B Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30, 2114–2120 (2014). [PubMed: 24695404]
56. Love MI, Huber W & Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15, 1–21 (2014).
57. Hänzelmann S, Castelo R & Guinney J GSVA: Gene set variation analysis for microarray and RNA-Seq data. *BMC Bioinformatics* 14, 1–15 (2013). [PubMed: 23323762]
58. Li W et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. *Genome Biol* 15, 554 (2014). [PubMed: 25476604]


59. Brinkman EK, Chen T, Amendola M & Van Steensel B Easy quantitative assessment of genome editing by sequence trace decomposition. *Nucleic Acids Res* 42, e168–e168 (2014). [PubMed: 25300484]
60. Korsunsky I et al. Fast, sensitive and accurate integration of single-cell data with Harmony. *Nature Methods* 2019 16:12 16, 1289–1296 (2019).
61. van Dijk D et al. Recovering Gene Interactions from Single-Cell Data Using Data Diffusion. *Cell* 174, 716–729.e27 (2018). [PubMed: 29961576]
62. Gu Z, Eils R & Schlesner M Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* 32, 2847–2849 (2016). [PubMed: 27207943]
63. Aran D et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nature Immunology* 2019 20:2 20, 163–172 (2019).
64. Andreatta M & Carmona SJ UCell: Robust and scalable single-cell gene signature scoring. *Comput Struct Biotechnol J* 19, 3796–3798 (2021). [PubMed: 34285779]
65. Kushnareva Y et al. Functional Analysis of Immune Signature Genes in Th1\* Memory Cells Links ISOC1 and Pyrimidine Metabolism to IFN- $\gamma$  and IL-17 Production. *J Immunol* 206, 1181–1193 (2021). [PubMed: 33547171]
66. Ye Q et al. HORMA Domain Proteins and a Trip13-like ATPase Regulate Bacterial cGAS-like Enzymes to Mediate Bacteriophage Immunity. *Mol Cell* 77, 709–722.e7 (2020). [PubMed: 31932165]
67. MacLean B et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. *Bioinformatics* 26, 966–968 (2010). [PubMed: 20147306]
68. Trindade BC et al. The cholesterol metabolite 25-hydroxycholesterol restrains the transcriptional regulator SREBP2 and limits intestinal IgA plasma cell differentiation. *Immunity* 54, 2273–2287.e6 (2021). [PubMed: 34644558]



**Figure 1. Functional genetics *in vivo*, metabolomics and transcriptional analysis of *ex vivo* populations of memory CD8 T cells identify a graded upregulation of a Srebp2-dependent metabolic programming across T<sub>RM</sub>.**


**a**, Experimental design and data analysis approach for an *in vivo* CRISPR/Cas9-mediated loss-of-function screen of metabolic regulators of memory CD8 T cell differentiation in LCMV infection. **b**, Unsupervised hierarchical clustering heatmap of averaged gene essentiality scores for significant genes in SI T<sub>RM</sub> in both libraries. **c**, Unsupervised hierarchical clustering of scaled averaged enrichment scores of significant metabolic signatures in SI T<sub>RM</sub> in both libraries. **d**, PCA of relative metabolite abundances of indicated P14 CD8 T cells 13 days after LCMV infection. **e**, Abundance of selected identified annotated metabolites of mevalonate/cholesterol synthesis pathway on indicated P14 CD8 T cells. T<sub>N</sub>, Naïve. **f**, Mevalonate/cholesterol synthesis pathway GSEA scores from RNAseq analysis of indicated P14 CD8 T cells, GSE107278. **g**, Mevalonate/cholesterol synthesis pathway GSEA scores from RNAseq analysis of indicated memory P14 CD8 T cells (>30 days pi), GSE182276. SG, salivary gland. WAT, white adipose tissue. **h**, PageRank scores

and gene expression of Srebp2 and Runx3 in memory P14 CD8 T cells, GSE182276. **i**, Representative detection of Srebp2 and CD103 by immunofluorescence of congenically labeled memory P14 CD8 T cells. Scale bar, 20 $\mu$ m. P14 CD8 T cells recovered from tissues other than the spleen were pregated on IV<sup>-</sup> populations. Images are representative of 2 independent experiments (**i**). Data are mean  $\pm$  s.e.m., and representative of at least two independent experiments (**f**, **g**) with a total of n=2 (day 35) and n=3 (day 7) (**f**), n=2 (liver and WAT), n=3 (SG, kidney, and SI), n=4 (blood), and n=5 (spleen) (**g**) mice, or one experiment (**a**, **b**, **c**, **d** and **e**), with a total of n=7 (Lib7) and n=9 (Lib5) mice pooled per library (**a**, **b**, and **c**), and n=3 (SI), n=4 (T<sub>N</sub> and kidney), and n=5 (rest) (**d** and **e**) samples, where each sample contains cells pooled cells from 2 to 5 mice. Two-sided un-paired t-Test (**e**, **f**, and **g**). \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ < 0.005.




**Figure 2. An Srebp2-dependent metabolic program controls SI TRM formation.**  
**a-c**, Ratio of transduced transferred P14 CD8 T cells (**a** and **b**), or P14 Cas9eGFP CD8 T cells (**b**), harvested from indicated tissues at indicated times after LCMV (**a** and **b**), or LM-GP<sub>33-41</sub> (**c**) infection, evaluated by flow cytometry. **d**, Number of total Tet<sup>+</sup> cells in the spleen, and total Tet<sup>+</sup> TRM cells in the SI, kidney, and liver of *Scap<sup>fl/fl</sup> Cd4-Cre<sup>+</sup>* and *Scap<sup>wt</sup> Cd4-Cre<sup>+</sup>* at indicated times after LCMV infection. **e**, LCMV titers measured by qPCR in the SI of WT and *Scap* KO mice previously infected with LM-GP<sub>33-41</sub> 3days after LCMV rechallenge. NP, nucleoprotein. GP, glycoprotein. **f**, Number of total P14 CD8

T cells isolated from indicated tissues at days 7 and 21 after LCMV infection in mice treated with vehicle or Lovastatin (Lova). **g**,  $T_{RM}$  scores of human CD8 T cells of the blood and SI profiled by scRNAseq grouped by statin use; no statins = 8 donors, statins = 5 donors. **h**, Ratio of total P14 CD8 T cells from indicated tissues in mice fed high versus low-cholesterol-containing diet. Data are geometrical distributions of single-cell gene expression values with median values (**g**) or mean  $\pm$  s.e.m. and representative of two independent experiments (**a**, **b**, **d**, **e** and **f**), or pooled from two independent experiments (**c**, **e**, **f**, and **h**), with a total of  $n=7$  (**a**),  $n=7$  (**b**),  $n=7$  (**c**),  $n=8$  (**d**),  $n=6$  in WT and  $n=7$  in Scap KO (**e**),  $n=9$  (day 7) and  $n=4$  (day 21) (**f**), and  $n=3$  (mLN, kidney, and liver day 7, and liver day 40), and  $n=6$  (rest) (**h**) mice. Two-sided unpaired (**f**), and paired t-Test, (**a**, **b**, **c**, **d**, **f**, **g**, and **h**), two-sided Mann-Whitney U Test (**e**). \* $P<0.05$ , \*\* $P<0.01$ , \*\*\* $P<0.005$ . Two-sided one-sample t-Test (**a-c**, and **h**) # $P<0.05$ , ## $P<0.01$ , ### $P<0.005$ . Two-way ANOVA (**d**) ## $P<0.01$ .



**Figure 3. Non-steroidal products of the mevalonate/cholesterol synthesis pathway mediate TRM adaptations.**


**a**, Unsupervised hierarchical clustered heatmap of gene essentiality scores for genes related to the mevalonate/cholesterol synthesis pathway in the cellular populations profiled in our *in vivo* CRISPR/Cas9-mediated loss-of-function screen. Blue and red denote positive and negative regulators of memory CD8 T cell formation, respectively. **b,c**, Ratio of indicated transduced transferred P14 Cas9eGFP CD8 T cells, *sgHpd* (**b**) and *sgFdf1* (**c**), harvested from indicated tissues at indicated times after LCMV infection, evaluated by flow cytometry. **d**, Targeted *in vivo* CRISPR/Cas9-mediated loss-of-function screen of mediators of the effect of *Fdf1* deletion on CD8 T cell memory formation. Data visualization represents the enrichment as  $\text{Log}_2\text{FC}$  of sgRNA frequencies in sgCD19 outputs versus *sgCd19* input (x axis), and *sgFdf1* outputs versus *sgFdf1* input (y axis), for each effector and memory CD8 T cell subset. **e**, Ratio of transduced transferred P14 CD8 T cells harvested from indicated tissues at indicated times after LCMV infection, evaluated by flow cytometry. **f**, Total cell numbers of Empty and *Pds2* OE SI IEL P14 CD8 T cells in mice fed low or high cholesterol-containing diets. Data are mean  $\pm$  s.e.m.. and representative or pooled from at least two independent experiments (**b**, **c**, **e**, and **f**), or one experiment (**d**), with a total of  $n=7$  (day 7) and  $n=9$  (day 14) (**b**, **c**),  $n=9$  (**c**),  $n=6$  (**d**),  $n=6$  (day 7) and  $n=7$  (day 14) (**e**),  $n=4$  (**f**) mice. Two-sided unpaired t-Test (**b**, **c**, **e**, and **f**) \* $P<0.05$ , \*\* $P<0.01$ , \*\*\* $P<0.005$ . Two-sided one-sample t-Test (**b**, **c**, and **e**) # $P<0.05$ .



**Figure 4. Pdss2 expression is required and sufficient to promote mitochondrial respiration and CoQ synthesis in CD8 T cells.**

**a**, Oxygen consumption rate (OCR) of *in vitro* activated sh*Cd19* and sh*Srebf2* CD8 T cells subjected to the MitoStress test (Seahorse). Oligomycin (O), FCCP (F), Rotenone/ Antimycin A (R/A). **b**, Oxygen consumption rate (OCR) of *in vitro* activated CD8 T cells treated with statin (simvastatin) in combination with mevalonolactone (MVA) or cholesterol (Chol.) and subjected to the MitoStress test (Seahorse). **c**, OCR of *in vitro*-activated sg*Cd19* and sg*Pdss2* Cas9eGFP CD8 T cells subjected to the MitoStress test (Seahorse). **d**, OCR of *in vitro* activated sg*Cd19* and sg*Fdft1* Cas9eGFP CD8 T cells subjected to the MitoStress test (Seahorse). **e**, OCR of *in vitro* activated sg*Cd19*, sg*Fdft1*, and sg*Fdft1/Pdss2* Cas9eGFP CD8 T cells subjected to the MitoStress test (Seahorse). **f**, OCR of *in vitro* activated empty vector control (Empty) and *Pdss2* OE CD8 T cells subjected to the MitoStress test (Seahorse). **g**, Quantification of CoQ and demethoxyubiquinone (DMQ) species in *in vitro* activated sg*Cd19* and sg*Fdft1* Cas9eGFP CD8 T cells normalized to total protein content. **h**, Quantification of CoQ and DMQ species in *in vitro* activated Empty and *Pdss2* OE CD8 T cells normalized to total protein content. Data are mean  $\pm$  s.e.m. and representative of at least two independent experiments (**a-h**), with a total of n=4 (**a**), n=5 (**b**), n=3 (**c**), n=2 (**e**), n=3 (**f**), n=3 (**g**), n=5 (**h**) cell replicates. Two-way ANOVA (**a**, **c**, **d**, **e**, and **f**). Two-sided unpaired t-Test (**b**, **g**, and **h**) \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ < 0.005.





**Figure 5. Increased production of non-steroidal products of the mevalonate/cholesterol synthesis pathway is a common requirement for SI TRM and TIL.**

**a**, Targeted *in vivo* screen of mevalonate/cholesterol synthesis pathway genes for SI TRM formation in LCMV infection, and CD8 T cell accumulation in dLN and MC38-GP<sub>33-41</sub> tumors. **b**, Venn diagram of significant genes (*fdr* < 0.01; dLN and TIL, *fdr* < 0.01 and Log<sub>2</sub>FC < -2, SI TRM) from (a). **c**, Log<sub>2</sub>FC of sgRNA frequencies for each screen from a. **d**, Metabolic pathway with relevant genes from a. **e-g**, Ratio of indicated transduced P14 CD8 T cells (e,g) or P14 Cas9eGFP CD8 T cells (f) in indicated tissues 5–7 days after adoptive cell transfer (ACT). **h**, MC38-GP<sub>33-41</sub> tumor growth curves of mice receiving indicated transduced P14 Cas9eGFP CD8 T cells. **i**, Cell frequencies and total numbers of transduced P14 Cas9eGFP CD8 T cells in MC38-GP<sub>33-41</sub> tumors, dLN, and spleens 4 days after ACT. **j**, B16-GP<sub>33-41</sub> tumor growth curves in mice adoptively transferred with indicated transduced P14 CD8 T cells. **k**, Cell frequencies in Empty and *Pdss2* OE P14 CD8 T cells in MC38-GP<sub>33-41</sub> tumors. **l**, B16-GP<sub>33-41</sub> tumor growth curves of mice receiving

indicated treatments. **m**, Proposed model of the Srebp2-dependent metabolic programming of SI T<sub>RM</sub> and TIL. Data are mean  $\pm$  s.e.m. and representative or pooled from of at least two independent experiments (**e-l**), with a total of n=4 (SI T<sub>RM</sub>) and n=5 (tumor) (**a-c**), n=9 (**e**), n=8 (**f**), n=8 (**g**), n=3 (no transfer), n=15 (sg*Cd19*), and n=16 (sg*Fdft1*) (**h**), n=8 (**i**), n=9 (sg*Cd19*) and n=7 (sg*Pdss2*) (**j**), n=13 (**k**), n=10 (veh) and n=13 (rest) (**l**) mice, and one experiment (**a-c**), with n=3–5 mice pooled in each sample (**a-c**). Two-sided unpaired (**f** and **i**) and paired (**e**, **g**, and **k**) t-Test. Two-way ANOVA (**h** and **j**). Pearson correlation (r) (**c**). Fisher's exact test (**l**). \**P*<0.05, \*\**P*<0.01, \*\*\**P*< 0.005. Two-sided one-sample t-Test (**e** and **g**) #*P*<0.05, ###*P*<0.005.